PROGRAM

ISBER

GLOBAL BIOBANKING CONGRESS

Shenzhen CHINA

APRIL 21-23, 2026

Trust History. Trust MVE.

MVE Biological Solutions is the global leading manufacturer of cryogenic storage and shipping devices for over 60 years. Trust History. Trust MVE.

Best-In-Class Cryogenic Storage with New Controller

MVE's New HE freezer with CryoVerse™ Connect Controller

Extended Hold Time Vapor Shipper

MVE's New SC 4/2 V Vapor Shipper

Innovative Condition Monitoring Technology

MVE's New Integrated Condition Monitoring Platform

Solutions for all your cryogenic storage and shipping needs

Storage → Shipping → Monitoring

MVE® Biological Solutions

mvebio.com

csasia@mvebio.com

Table of Contents

Message from the Presidents (BBCMBA, ISBER, BGI)

Dear Delegates,

It is with great pleasure that we welcome you to the World Biobanking Congress 2026, taking place April 21-25, 2026 in Shenzhen, China. This landmark event represents an exceptional collaboration between three leading biobanking associations: the International Society for Biological and Environmental Repositories (ISBER), the Biobank Branch, China Medicinal Biotech Association (BBCMBA), and BGI.

The 2026 Congress will bring together two major events: the ISBER Global Biobanking Congress (April 21-23), at the BGI Center (No.9 Yunhua Road, Yantian District, Shenzhen, 518085, China), and the BBCMBA 18th China Holistic Integrate Biobankology Conference and the 13th Hospital Dean's Summit on Biobank (April 23-25), held at Shenzhen Dameisha Coastal Hotel (9 Yankui Road, Dameisha, Yantian District, Shenzhen, 518083, P.R.China). The joint collaborative day on April 23 will take place at the BGI Center, marking a pivotal occasion for international partnership, shared learning, and innovation.

As one of China's most dynamic and forward-thinking cities, Shenzhen provides a fitting backdrop for this global gathering. Home to BGI and numerous leading biotechnology companies, the city embodies rapid scientific advancement, a strong spirit of innovation, and an open environment for international cooperation, making it an ideal setting for advancing the future of biobanking.

We are inviting you to register for either or both meetings, with a special discounted rate available for those attending both. This unique opportunity allows participants to engage with two major biobanking communities, gain a broader perspective on global practices and research, and strengthen international collaborations.

With warm regards,

Dr. Gregory Grossman,
ISBER President

Dr. Hengjun Gao,
BBCMBA President

Dr. Xun Xu,
BGI Research

About Our Partnering Organizations

ISBER is the only global society dedicated to harmonizing the scientific, technical, legal, and ethical issues relevant to repositories of biological and environmental specimens. Established in 1999, ISBER fosters collaboration, education, and innovation across the global biobanking community and has made its annual conference the premier international event for biobanking education and best practices.

BBCMBA, founded in 2009, is a national committee dedicated to advancing the standardization, education, and full utilization of biobank resources in China. Its slogan—Industry Standard, Education and Training, Academic Communication, and International Cooperation—reflects its commitment to building a strong and interconnected biobanking community.

BGI is one of the world's leading life science and genomics organizations, with partnerships in over 100 countries. Its global headquarters in Shenzhen, completed in 2023, includes a state-of-the-art International Convention Center, providing the ideal venue for hosting the ISBER Global Biobanking Congress and fostering international scientific exchange.

We look forward to welcoming you to Shenzhen for this joint gathering of the global biobanking community. Together, we will share knowledge, explore innovations, and shape the future of biobanking worldwide.

GLOBAL BIOBANKING CONGRESS

Shenzhen CHINA
APRIL 21-23, 2026

Vision

ISBER advances the expertise and quality of biorepositories and biobanking science worldwide.

Mission

To be the leading network in the global biobanking and biorepository community.

Goals

- Disseminate information on repository management issues
- Educate and share information and tools within the society and with stakeholders
- Act as the voice for repositories to influence regulations and policy
- Develop best practice guidelines
- Provide centralized information about existing repositories
- Bring members together to work on emerging issues

INTERNATIONAL SOCIETY FOR BIOLOGICAL AND ENVIRONMENTAL REPOSITORIES

International Society for Biological and Environmental Repositories
1618 Station Street, Vancouver, BC, V6A1B6 Canada | T 604.484.5693

isber

INTERNATIONAL SOCIETY FOR BIOLOGICAL AND ENVIRONMENTAL REPOSITORIES

JOIN OR RENEW

INDIVIDUAL MEMBERSHIP

NETWORK WITH YOUR BIOBANKING COMMUNITY

Join the over 1,200 ISBER Global Members online and live at events.

Discounted registration rates of $400+ for ISBER Annual and Regional Meetings

Access to ISBER active Members-Only Forums, and the Member Directory

TRANSLATION OF BEST PRACTICES

isber Best Practices *Fifth Edition*

Translations now available in English, Chinese, Japanese, Spanish, and Persian for download on the ISBER website! Visit our Amazon page to purchase printed copies (available in English, Japanese, and Spanish).

Download the *Best Practices* at www.isber.org/bestpractices

Message from the Scientific Program Co-Chairs

Greetings to the ISBER and BBCMBA Community!

It is a privilege to address the esteemed members of both ISBER and BBCMBA.

Celebrating Collaboration of the World Biobanking Congress 2026

As we join together in anticipation of the World Biobanking Congress 2026, we celebrate the remarkable collaboration between our organizations. This unity reflects our shared commitment to advancing the field of biobanking and underscores the importance of working collectively to achieve common goals. By fostering partnerships and encouraging the exchange of ideas, we strengthen our ability to innovate and address challenges within the global biobanking community. Our collaboration sets the stage for a successful congress, where meaningful progress and impactful advancements can be realized.

Major International Events at the World Biobanking Congress 2026

The World Biobanking Congress 2026 will host two prominent international events. The first is the 2026 ISBER Global Biobanking Congress: Global Collaboration for Advanced Technology and Innovation, which will be held at the BGI Center. This congress will bring together global leaders and experts in biobanking to focus on international partnerships, technological advancement, and innovative practices within the field.

Following this, the BBCMBA 18th China Holistic Integrate Biobankology Conference and the 13th Hospital Dean's Summit on Biobank will take place at the InterContinental Shenzhen Dameisha Resort. These gatherings will provide additional opportunities for networking, knowledge sharing, and collaboration, emphasizing the integration of biobankology and the strategic role of biobanks in healthcare and research.

Collaborative Day: April 23rd

A key highlight of the congress will be the collaborative day on April 23rd. This joint session will serve as a central platform for fostering international partnership, promoting shared learning, and driving innovation within the global biobanking community.

ISBER's Commitment to Global Engagement and Program Enhancement

As the global biobanking community continues to grow and evolve, ISBER recognizes the importance of adapting its flagship meetings to better serve the needs of international partners. To reflect this commitment, ISBER is actively revising its program to provide a meeting experience that is more focused and educational. The goal is to foster enhanced global networking opportunities, ensuring that the international biobanking community can connect, share knowledge, and collaborate more effectively. Through these program changes, ISBER aims to strengthen ties among biobanking professionals worldwide and support the advancement of the field on a global scale.

2026 ISBER Theme: Global Collaboration for Advanced Technology and Innovation

The 2026 ISBER theme, Global Collaboration for Advanced Technology and Innovation, is crafted to highlight the growing significance of international partnerships in biobanking. By focusing on collaboration across borders, the theme underscores how these connections are essential for the development of new technologies and the cultivation of innovative approaches. The emphasis on advanced technology and innovation is meant to drive the adoption of emerging practices in biobanking, ensuring that the field continues to progress and evolve.

This thematic approach also demonstrates a dedicated commitment to bring together experts from around the globe. By sharing their knowledge and experiences, these professionals contribute to the advancement of biobanking as a discipline. The theme aims to promote meaningful progress by encouraging the exchange of ideas and fostering a culture of innovation within the international biobanking community.

Scientific Program Structure and Engagement Opportunities

Guided by the ISBER Program Planning Task Force, the scientific program is developed to ensure each day begins with an engaging and visionary keynote speaker. These sessions will set the tone for a day filled with dynamic presentations. Following the keynote, the agenda features abstract submissions from the global biobanking community, providing attendees with valuable insights into current research and developments.

In addition to scientific sessions, the program incorporates educational and corporate workshops, interactive roundtables, and dedicated networking opportunities. This approach creates a stimulating environment where attendees can actively contribute to discussions, foster connections, and showcase their work to an international audience.

Biobanking: Career Opportunities and Strategic Importance

Throughout the congress, attendees will develop a deeper understanding of biobanking as both a dynamic and rewarding professional field. The sessions and discussions will illustrate how biobanking serves as a crucial element within the broader research infrastructure. By highlighting the strategic role biobanking plays, the content will emphasize its contribution to solving pressing global challenges and celebrating significant achievements in the field. This renewed appreciation aims to inspire participants and reinforce the importance of biobanking in advancing scientific progress.

Recognition of Partners, Sponsors, and Vendors

This year's World Biobanking Congress owes its success to the invaluable support of our partners. We are especially grateful to BGI Research and Shanghai Outdo Biotech Co. Ltd, whose essential support and guidance were fundamental in organizing the first World Biobanking Congress. Their dedicated efforts have played a pivotal role in bringing this event to fruition and in advancing our shared mission within the biobanking community.

We also wish to express our appreciation to our sponsors and vendors. Their generous contributions—ranging from products and technology to professional resources—are vital in ensuring biobanks can function with optimal efficiency, effectiveness, and impact. We encourage all attendees to visit the exhibit hall, where they can connect directly with these sponsors, explore the innovative solutions on display, and learn more about the resources available. Engaging with our sponsors not only strengthens the biobanking community but also helps foster meaningful relationships that support ongoing advancement in the field.

Thank you for joining us.

Warm regards,

World Biobanking Congress 2026 Program Planning Co-Chairs
Jason Chen, Deb Leiolani Garcia, Charles Weiye Wang & Xiaoyan Zhang

2025-2026 ISBER Board of Directors and Community of Practice Chairs

ISBER BOARD

Gregory Grossman, *PhD, CCRP, BCMAS, CEBT*
PRESIDENT-OF-THE-BOARD
May 2025 - May 2026
Advancing Sight Network/ Precision Ocular Biobank
Alabama, United States

Stella Somiari, *PhD, MBA*
PRESIDENT ELECT-OF-THE-BOARD
May 2025 - May 2026
Windber Research Institute
Pennsylvania, United States

Dayong Gao, *PhD, BSc*
PAST PRESIDENT-OF-THE-BOARD
May 2025 - May 2026
University of Washington
Washington, United States

Anusha Hettiaratchi, *PhD*
TREASURER
May 2025 - May 2028
University of New South Wales
Sydney, Australia

Rebecca Pugh, *MS*
SECRETARY
May 2023 - May 2026
National Institute of Standards and Technology
South Carolina, United States

William Schleif, *PhD*
DIRECTOR-AT-LARGE - Americas
May 2023 - May 2026
Johns Hopkins All Children's Pediatric Biorepository
Florida, United States

Jason Chen, *BS*
DIRECTOR-AT-LARGE - China
May 2024 - May 2027
BGI Research
Guangdong, China

Engela Conradie, *PhD, Pr.Sci.Nat*
DIRECTOR-AT-LARGE - Europe, Middle East, Africa
May 2022 - May 2028
Centre for Human Metabolics
Potchefstroom, South Africa

Wayne Ng, *PhD, GAICD*
DIRECTOR-AT-LARGE - Indo-Pacific Rim
May 2023 - May 2026
Victorian Cancer Biobank
Melbourne, Australia

Dana Cooper, *MBA, BKin, CAE*
EXECUTIVE DIRECTOR
Ottawa, Ontario

COMMUNITY OF PRACTICE CHAIRS

Marianne Henderson, *MS, CPC PMP*
EDUCATION AND TRAINING COMMUNITY OF PRACTICE
National Cancer Institute
Maryland, United States

Rita Lawlor, *PhD, CIPP/E, CIPM*
SCIENCE POLICY COMMUNITY OF PRACTICE
ARC-NET Centre for Applied Research on Cancer
Verona, Italy

Samantha Higgins, *MSc, BSc*
STANDARDS COMMUNITY OF PRACTICE
Victorian Cancer Biobank
Melbourne, Australia

ISBER Award Recipients

Please join us in celebrating the 2026 award recipients at the ISBER Awards Ceremony, presented by Dr. Stella Somiari, President-Elect of the ISBER Board, taking place on Tuesday, April 21 at 13:30 in Functional Hall 1.

ISBER AWARD FOR OUTSTANDING ACHIEVEMENT IN BIOBANKING

Awardee:
María Teresa García de Dávila, MD, PhD

Dr. María Teresa García de Dávila is currently a Board Member and President of the Garrahan Foundation in Buenos Aires, Argentina. She graduated in Medicine and later specialized in Pathology at the University of Córdoba, Argentina, and obtained her PhD in Medicine from the University of Buenos Aires. Prior to joining the Garrahan Foundation, she worked for more than 30 years at Garrahan Hospital, where she was Chair of the Department of Pathology and Director of the Paediatric Tumour Bank. She has held her current leadership role at the Foundation since 2001.

ISBER SPECIAL SERVICE AWARDS

Special Service Award recipients will be announced during the Congress.

NEW INNOVATION PRODUCT AWARD

The two co-recipients for the 2026 New Innovation Product Award are:

Specie Bio's "AI Chat and Matching Engine"

SpecieBio
BioExchange: Where Science Meets Access

Servare Biotechnology (Ningbo) Co., Ltd's "The Automatic Perfusion Master"

SERVARE

Congratulations to our co-recipients! Find these companies in the exhibit hall to learn more about these exciting new products.

ISBER LEADERSHIP AWARD

Awardee:
Clare Allocca

Clare Allocca is a retired Physical Scientist and Senior Advisor for Standardization in the Standards Coordination Office at NIST. Clare has led and supported extensive standardization and conformity assessment activities, and held multiple chair, secretariat, and convenor roles, both internationally and domestically, within ISO/TC276 *Biotechnology*, ISO/TC276/SC1 *Analytical methods for Biotechnology*, and IEC-ISO/JTC3 *Quantum technologies*. As an expert of ISO/TC276/WG2 *Biobanking & bioresources*, she co-authored ISO 20387:2018 *Biotechnology - Biobanking – General requirements for biobanking* and its implementation guide. Clare is Past President for the International Society for Biological and Environmental Repositories (ISBER) and past Vice-Chair of the ISBER Standardization Community of Practice. She has 40 years of experience in research and development, program management, technology management, strategy, and standardization.

Clare holds S.B. degrees in *Materials Science and Engineering* and *Geochemistry*, from the Massachusetts Institute of Technology, an M.S. degree in *Ceramic Engineering* from the University of Illinois at Urbana-Champaign, and an Executive Master of *Management of Technology* jointly from the University of Pennsylvania Wharton Business School and School of Engineering.

MVE Biological Solutions

Award sponsored by MVE Biological Solutions

Thank you to our 2026 Sponsors & Exhibitors

Genepoint

Haier Biomedical
Intelligent Protection of Life Science

Hisense

iKelvin 艾尔温

Orcella

Agilent
Trusted Answers

ASKION

AZENTA
LIFE SCIENCES

BIOZY
LIFE SCIENCE TECHNOLOGY

Cryo Bio System

华大智造 MGI

Cryotherm

驰川科技
GALLOPSTEED SCI-TECH CO.,LTD

SERLNG

LiCONiC
INSTRUMENTS

LVL
technologies

MVE
Biological Solutions

Nexpring
Health™

NOBLEGEN
cryogenics

SERVARE

B°Cryo
Systems

SpecieBio
BioExchange: Where Science Meets Access

ThermoFisher
SCIENTIFIC

SORFA
SORFA LIFE SCIENCE

General Congress Information

VENUE

BGI Center, No.9 Yunhua Road, Yantian District, Shenzhen, 518085, China (华大时空中心)

LANGUAGE

The official language of the ISBER congress (April 21-23) is English. All sessions will be conducted in English.

HOTEL OPTIONS

All hotels are located approximately 10–15 minutes by car from the congress venue. A complimentary shuttle service will transport delegates between the designated hotels (below) and the conference venue, the BGI Center. Please see "Shuttle Bus Schedule" section for the schedule.

- **Kingkey Palace Hotel** 大梅沙京基海湾大酒店
  - Address: No. 90 Yanmei Road, Yantian District, Shenzhen, 518083
- **Intercontinental Shenzhen Dameisha Resort** 深圳大梅沙京基洲际度假酒店
  - Address: No. 9 Yankui Road, Dameisha Yantian District, Yantian, Shenzhen
- **MGM Shenzhen** 深圳美高梅酒店
  - Address: 33 Yanmei Rd, Yantian District, Shenzhen, Guangdong Province, China, 518000

WI-FI INTERNET CONNECTION AT BGI

BGI is providing complimentary wifi for guests of the Congress.

- **Wi-Fi Name:** ISBER
- **Wi-Fi Password:** 202604

We ask you to avoid downloading heavy files, movies or music during the Congress as it will affect the connection speed for other attendees.

REGISTRATION & INFORMATION

Foyer area

- Monday, April 20: 9:30 – 17:00
- Tuesday, April 21: 7:30 – 17:30
- Wednesday, April 22: 7:30 – 18:15
- Thursday, April 23: 7:30 – 16:00

SPEAKER SERVICES

Speaker Services Room near Functional Hall 1

Keynote speakers and session presenters are asked to bring presentations on a USB flash drive to the AV session room at least 24 hours prior to their scheduled presentation to ensure files are uploaded and ready.

The AV room will be staffed during the following hours:

- Tuesday, April 21: 7:30 – 17:30
- Wednesday, April 22: 7:30 – 18:15
- Thursday, April 23: 7:30 – 16:00

EXHIBIT HALL HOURS

Foyer area

Take advantage of networking and lunch breaks to connect with exhibitors, and be sure to visit them during the Welcome Reception on April 21 and the Exhibitor Reception on April 22.

- Tuesday, April 21: 11:00 – 19:00
- Wednesday, April 22: 10:00 – 19:45
- Thursday, April 23: 10:00 – 15:15

EXHIBITOR LISTING

Agilent Technologies 安捷伦科技有限公司	C30
Askion GmbH	C31
Azenta Life Sciences	C10 / C11
Biozy Life Sciences Technology (Jiangsu) Co., Ltd 江苏臻远生物科技有限公司	C25
CRYO BIO SYSTEM	C06
Cryotherm GmbH & Co.KG	C22
GALLOPSTEED SCI-TECH CO.,LTD 骅川（上海）科技有限公司	C08 / C09
Genepoint Technologies	A05
Haier Biomedical 海尔生物医疗	A02
Jiangsu SERLNG New Energy Technology	C32 / C33
Liconic	C27

EXHIBITOR LISTING

LVL technologies GmbH & Co. KG	C34
MGI Tech Co., Ltd. 深圳华大智造销售有限公司	C07
MVE Biological Solutions	C01 / C02
Nexpring Health	C15
Peak Scientific Instruments Shanghai Ltd (Noblegen Cryogenics) 毕克气体仪器贸易（上海）有限公司	C29
Origincell	A01
Qingdao Hisense Commercial Cold Chain Co., Ltd. 青岛海信商用冷链股份有限公司	A06

Servare Biotechnology(Ningbo) Co., Ltd. 赛维尔生物科技（宁波）有限公司	C28
Shanghai iKelvin Life Science & Technology Co., Ltd 上海艾尔温生命科技有限公司	A03
Sichuan B Cryogenic Systems Co., Ltd. 四川贝纳吉低温设备有限公司	C13 / C14
Specie Bio	C03
Thermo Fisher Scientific	C04 / C05
Zhejiang Sorfa Life Science Research Co., Ltd. 浙江硕华生命科学研究股份有限公司	C26

SHUTTLE BUS SCHEDULE

Complimentary shuttle bus service will be provided for registered attendees between BGI and the official conference hotels: Kingkey Palace Hotel, Intercontinental Shenzhen Dameisha Resort, and MGM Shenzhen.

Shuttles will operate according to the schedule below, offering convenient transportation to and from the venue throughout the meeting.

Date	From Hotels to BGI Centre	
April 21, 2026	**MGM**	
	First bus	7:05
	Second bus	7:20
	Intercontinental	
	First bus	7:13
	Second bus	7:28
	Kingkey Palace	
	First bus	7:15
	Second bus	7:30
	BGI	
	First bus	7:30
	Second bus	7:45
	From BGI Center to Hotels	
	BGI	
	First bus	19:00
	Second bus	19:20
	Kingkey Palace	
	First bus	19:15
	Second bus	19:35
	Intercontinental	
	First bus	19:17
	Second bus	19:37
	MGM	
	First bus	19:25
	Second bus	19:45

Date	From Hotels to BGI Centre	
April 22, 2026	**MGM**	
	First bus	6:50
	Second bus	8:05
	Intercontinental	
	First bus	6:58
	Second bus	8:13
	Kingkey Palace	
	First bus	7:00
	Second bus	8:15
	BGI	
	First bus	7:15
	Second bus	8:30
	From BGI Center to Hotels	
	BGI	
	First bus	19:30
	Second bus	19:45
	Kingkey Palace	
	First bus	19:45
	Second bus	20:00
	Intercontinental	
	First bus	19:47
	Second bus	20:02
	MGM	
	First bus	19:55
	Second bus	20:10

Date	From Hotels to BGI Centre	
April 23, 2026	**MGM**	
	First bus	6:50
	Second bus	7:20
	Intercontinental	
	First bus	6:58
	Second bus	7:28
	Kingkey Palace	
	First bus	7:00
	Second bus	7:30
	BGI	
	First bus	7:15
	Second bus	7:45
	From BGI Center	
	BGI	
	First bus to hotels	16:45
	To the Red Lantern Celebration only	16:45
	Kingkey Palace	
	First bus	17:00
	Intercontinental	
	First bus	17:02
	MGM	
	First bus	17:10

ONSITE REGISTRATION & ACTIVITIES

All delegates are encouraged to register for the meeting prior to arriving on-site, though on-site registrations will be available. The ISBER Global Biobanking Congress offers several fun, networking activities that are not included with your registration but can be purchased at the registration desk. ***Note: both the 10:30 and the 16:30 tours are sold out.*** You may check onsite at the registration desk to see if spaces have become available.

BGI Tour
Monday, April 20, 2026 10:30 | 16:30 *FREE*

Delegates will have the opportunity to visit the BGI Center in Shenzhen, one of the world's leading genomics research facilities and the venue of the 2026 ISBER Congress. The tour offers attendees a firsthand look at cutting-edge innovations in genomics, sequencing, and biobanking technologies, providing valuable insights and inspiration for advancing their own research and repository practices. The tour is complimentary for registered delegates and will be held during the pre-congress day. Pre-Registration is mandatory.

Speed Networking
Wednesday, April 22, 2026 7:30 – 8:30 | $10 USD
Room 411

Whether you're new to the ISBER meeting or a returning attendee, start this Congress right with our popular Speed Networking event! Join fellow biobankers for lively one-on-one conversations in five-minute intervals, all while enjoying local delicacies and hot beverages. It's the perfect chance to make connections, spark collaborations, and meet peers from around the globe in a relaxed, fun setting.

The Red Lantern Celebration
Thursday, April 23, 2026 17:00 – 21:15 | $65 USD
Offsite Location – Please meet outside BGI to board the shuttle to the venue

Join ISBER for The Red Lantern Celebration, a memorable evening of dining and performance that brings Chinese history and culture to life. This immersive experience features:

- Live performances inspired by a Tang Dynasty wedding, led by professional dancers and musicians
- An imperial palace-style setting, with carefully designed décor and atmosphere
- A multi-course dinner inspired by ancient imperial cuisine, with each dish rooted in tradition and storytelling

This special event offers a unique opportunity to connect with fellow delegates while experiencing an unforgettable cultural evening in Shenzhen. As part of the theme of the event, we encourage guests to dress in black, red, or gold to help create a festive and elegant atmosphere.

Your ticket includes round-trip transportation from the BGI to the venue, and back to the conference hotels. Plus, +1 guests, friends, and colleagues are welcome to join—simply purchase an additional ticket on the website or at the registration desk!

CERTIFICATES OF ATTENDANCE

All attendees will receive a certificate of attendance electronically upon completing the post-congress delegate evaluation. This will be distributed via email following the meeting.

POSTER PRESENTATION INFORMATION

Poster hall at BGI

- Poster Set-Up:
  - Monday, April 20: 9:30 – 17:00
  - Tuesday, April 21: 7:00 – 9:00
- Poster Tear-Down:
  - Thursday, April 23 15:15 – 17:00

Please make sure your posters are set up and torn down during these designated times. Posters not taken down after the designated time may be disposed of by the ISBER Head Office.

Poster Presentation Times:
We ask that you stand by your poster during the days and times outlined below to maximize opportunities to network and discuss your research with delegates. Receptions are listed below:

- **Tuesday, April 21:**
  Welcome Reception (17:30 – 19:00)
  [Optional but encouraged]
  At the Welcome Reception, poster presenters are invited to be near their posters and interact with delegates if they wish! However, they are also welcome to network more broadly.
- **Wednesday, April 22:**
  Exhibitor & Poster Networking Evening (18:15 – 19:45) *[First hour required]*
  The first hour of the Exhibitor & Poster Networking Evening, 18:15 – 19:15, will be a dedicated poster networking time. Poster presenters are asked to be near their poster so that they can network and discuss their poster with other delegates.
- **Thursday, April 23:**
  General Lunch, Poster and Exhibits (12:15 – 12:45)
  This lunch provides an opportunity to present and highlight your work to BBCMBA delegates during the joint day.

Venue Map



Final layout may be different than depicted on this page.

Conference Program

This year's program is organized into five thematic tracks, serving as umbrella themes to help you personalize your schedule based on your areas of interest. Explore these themes in the program to start planning your Congress experience.

Browse through the following five, color-coded tracks:
Bench to Biobank to One Health | Biospecimen Research – The Science Behind the Sample | People, Policy & Biobanking | Smart Biobank: AI, Automation, Digitalization | Innovative Technology in Biobanking

MONDAY, APRIL 20, 2026 (PRE-CONFERENCE)

9:30 - 17:00	Registration Desk Open
10:30 & 16:30	**BGI TOUR** *(Pre-registration required)* Select your tour time during registration: tour 1 at 10:30 and tour 2 at 16:30

TUESDAY, APRIL 21, 2026

7:30			Shuttle bus arrives at BGI
7:45			Shuttle bus arrives at BGI
7:30 - 17:30 *Foyer Area*			Registration and Speaker Services Open
8:15 - 8:30 *Functional Hall 1*			**ISBER 2026 GLOBAL BIOBANKING CONGRESS – WELCOME ADDRESS**
	Networking	8:15 - 8:17	**Congress Welcome Remarks** *Jason Chen, Conference Co-Chair, China and Deb Leiolani Garcia, Conference Co-Chair, USA*
	Networking	8:17 - 8:19	**BGI Welcome** *Dr. XU Xun, BGI, China*
	Networking	8:19 - 8:27	**Lion Dance**
	Networking	8:27 - 8:30	**Welcome** *Dr. Dayong Gao, Past-President of the ISBER Board*
8:30 - 9:30 *Functional Hall 1*	Smart Biobank: AI, Automation, Digitalization		**KEYNOTE LECTURE: AI-POWERED BIOBANKING: LEVERAGING MACHINE LEARNING FOR MULTI-OMICS INSIGHT** *Prof. Chen Wan-Tao, MD, PhD, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China* *Introduction by Dr. Dayong Gao, Past-President of the ISBER Board* As biobanks evolve from static repositories into dynamic engines for biomedical discovery, they face the critical challenge of integrating and analyzing complex, high-dimensional multi-modal data derived from biospecimens. Genomic, proteomic, metabolomic, and pathology imaging datasets are often fragmented, inconsistently annotated, and analytically siloed, which severely curtails their translational potential for advanced disease research. We thus propose "AI-powered biobanking" as an essential conceptual and operational paradigm shift to overcome these limitations. This approach embeds artificial intelligence and machine learning not as peripheral tools but as integral components of the biobank's scientific infrastructure. By leveraging AI to model complex relationships across multi-omics layers, pathology images, and clinical variables, biobanks can synthesize heterogeneous data into coherent and interpretable knowledge. Central to this vision is the deployment of computational methods that facilitate scalable integration, automated quality assessment, and the extraction of robust predictive signals from large-scale biobank cohorts. Such capabilities empower biobanks to transcend their traditional role as data storage facilities and become active contributors to hypothesis generation and biomarker discovery. The success of this model hinges on the close alignment of computational innovation with rigorous biobanking practices and clinically grounded research questions. AI-powered biobanking, therefore, represents a strategic reorientation that redefines the biobank's role in the data-driven future of biomedical research, ensuring that biospecimen collections are intrinsically linked to intelligent, integrative analytics.
9:30 - 9:45			Short break - delegates move to next rooms

TUESDAY, APRIL 21, 2026

9:45 - 11:00 CONCURRENT *Functional Hall 1*	Smart Biobank: AI, Automation, Digitalization	**CONTRIBUTED PAPER SESSION 1 - SMART BIOBANK: AI, AUTOMATION, DIGITALIZATION** *Moderators: V Krishnan Ramanujan, Cedars Sinai, USA and Zach von Menchhofen, Cooperative Human Tissue Network (CHTN), University of Pennsylvania, USA*	
		9:45 - 9:47	**Introductions**
		9:47 - 9:59	**Human Genome Project 2 (HGP2)** *Xin Jin, BGI, China*
		9:59 - 10:11	**AI-Driven Framework for Full-Lifecycle Management of Biobank Dry Repositories** *Jingjing Jiang, Jingwei Zhiyun (Beijing) Technology, China*
		10:11 - 10:23	**Fulfilling the Promise of Biobanks for Innovation in Africa's Technological Era** *Kossi Fofo Kabo, Institut Pasteur de Dakar, Senegal*
		10:23 - 10:35	**An AI Assessment Model for Cancer Tissues Frozen H&E Sections before Distribution in Biobanks** *Menghong Sun, Fudan University Shanghai Cancer Center, China*
		10:35 - 10:47	**Design and Preliminary Implementation of an AI-Based Intelligent Management System for Biobanks** *Midie Xu, Fudan University Shanghai Cancer Center, China*
		10:47 - 11:00	**Q&A/Panel Discussion**
9:45 - 11:00 CONCURRENT *Functional Hall 2*	People, Policy & Biobanking	**CONTRIBUTED PAPER SESSION 2 - ETHICAL, LEGAL, SOCIAL IMPLICATIONS (ELSI)** *Moderators: Anna Michalska-Falkowska, Medical University of Bialystok, Poland and Shonali Paul, CloudLIMS.com, India*	
		9:45 - 9:47	**Introductions**
		9:47 - 9:59	**A MBirSA Statement On Benefit Sharing In Biobanking In South Africa** *Ciara Staunton, University of KwaZulu-Natal, South Africa*
		9:59 - 10:11	**A Study on the Sharing Mechanism under the General Hospital Biobanks from the Perspective of the Principle of Solidarity** *Yuqing Ji, Huashan Hospital Fudan University, China*
		10:11 - 10:23	**Consent in Biobanks in Europe and Worldwide: Models, Challenges, and Future Directions** *Judita Kinkorova, University Hospital Pilsen, Czechia*
		10:23 - 10:35	**Managing Incidental Findings at Qatar Biobank: Unintended Discoveries, Intended Outcomes** *Marwa Eldeeb, Qatar Foundation, Qatar*
		10:35 - 10:47	**Towards an International Ethical Framework for Banking and Secondary Research Use of Human Biospecimens and Associated Data: The Seattle Principles** *Marianna Bledsoe, Independent Consultant, USA*
		10:47 - 11:00	**Q&A/Panel Discussion**
11:00 - 19:00 *Exhibit Hall*	Exhibit Hall Open		
11:00 - 11:30 *Exhibit Hall*	Morning Networking Break		

TUESDAY, APRIL 21, 2026

11:30 - 12:30 CONCURRENT *Functional Hall 1*

ALL TRACKS

ISBER FLASH TALKS FROM POSTERS - SESSION 1
Moderators: Louise Ludow, Murdoch Children's Research Institute, Australia

11:30 - 11:35	**Introductions**
11:35 - 11:39	**Integrated Serum Metabolomics Reveal Distinct Metabolic Reprogramming and a Novel Diagnostic Classifer in Colorrectal Signet Ring Cell Carcinoma** *Hu Shiqi, Fudan University Shanghai, China*
11:39 - 11:43	**Biobank Network in Japan to Accelerate Progress Towards Genomic Medicine** *Soichi Ogishima, Tohoku Daigaku, Japan*
11:43 - 11:47	**Quality Control of Distributed Biospecimens: A Two-Year Linking Sample-Level OC to Clinical Metadata in Colorectoral Cancer Biobank** *Yanzi Gu, Fudan University Shanghai, China*
11:47 - 11:51	**Impact of Freezer Storage Duration on the Diagnostic Performance of Plasma p-tau181 and p-tau217 in Differentiating Clinical Stages of Alzheimer's Disease: A Cross-Sectional Study** *Lifang Zhao, Xuanwu Hospital Capital, China*
11:51 - 11:55	**A Lean Biobank for Pandemic Response: Maximizing Research Utility Via Case-Ascertained Enrollment in the Valido Study** *Bernal Cortes, Labot Biobank, Agencia Costarricense, Costa Rica*
11:55 - 11:59	**On-Demand Organoid Construction from Cryopreserved Tissue Archived Blocks for Gastronintestinal Cancers** *Qi Wang, Fudan University Shanghai, China*
11:59 - 15:03	**Optimized Protocol for Isolation and Characterization of Tumor-Educated Platelets for Liquid Biopsy Applications** *Miyuki Uno, Instituto do Câncer do Estado de São Paulo (ICESP), Brazil*
12:03 - 12:07	**Implementing an Autopsy Program: A Multidisciplinary Approach in HIV and Cancer Research** *Larissa Oliveira Amorim, Instituto do Cancer de Estado de Sao Paulo (ICESP), Brazil*
12:07 - 12:11	**Aier Eye Biobank: A National Distributed Network for Ophthalmic Genetic Resources** *Min Li, Aier Eye Institute, Central South University, China*

11:30 - 12:30 CONCURRENT *Functional Hall 2*

ALL TRACKS

ISBER FLASH TALKS FROM POSTERS - SESSION 2
Moderators: Deb Leiolani Garcia, Conference Co-Chair, USA

11:30 - 11:35	**Introductions**
11:35 - 11:39	**Bridging the Gap from Operational Function to Accreditable Quality: Implementation of a Unified Quality Management System Driven by Automated Processes and Digital SOPs at the MUB Biobank** *Anna Michalska-Falkowska, Uniwersytet Medyczny w Bialymstoku, Medizinische Universitat, Poland*
11:39 - 11:43	**Translating Human Intent into SQL: A Case of a PHP- based AI Bridge in an Academic Biorepository** *Zachery von Munchenhofen, University of Pennsylvania, USA*
11:43 - 11:47	**Emerging Fluorescence Technologies for Empowering Biospecimen Science Research in Biobanks** *V Krishnan Ramanujan, Cedars-Sinai, USA*
11:47 - 11:51	**Experience in Establishing Patient-Derived Organoid Models of Gynecologic Tumor** *Qiaoxiu Gu, Women's Hospital School of Medicine, Zhejian University, China*

11:30 - 12:30 CONCURRENT

ALL TRACKS

ISBER FLASH TALKS FROM POSTERS - SESSION 2

11:51 - 11:55	**Building a TCH-Featured, AI-Powered Biobank by Integrating Samples and Digital Data as Bioresources for Standardized Research and Clinical Translation** *Ziran Zhao, First Teaching Hospital of Tianjin, China*

TUESDAY, APRIL 21, 2026

12:30 - 13:30 *Exhibit Hall*	General Lunch, Posters, and Exhibits	
13:30 - 13:45 *Functional Hall 1*	**ISBER AWARDS CEREMONY** *Presented by Dr. Stella Somiari, President-Elect of the ISBER Board*	
13:45 - 14:00	Short break - delegates move to next rooms	
14:00 - 16:00 CONCURRENT *Functional Hall 1*	People, Policy, and Biobanking	**CONTRIBUTED PAPER SESSION 3 - BIOBANKING STRUCTURES & CROSS SECTION PARTNERSHIPS** *Moderators: V Krishnan Ramanujan, Cedars Sinai, USA and Anna Michalska-Falkowska, Medical University of Bialystok, Poland*
		14:00 - 14:02 **Introductions**
		14:02 - 14:14 **Development of a Community-Based Natural Population Cohort Biobank of Mental Disorders** *Xiaojie Zhang, The Second Xiangya Hospital of Central South University, China*
		14:14 - 14:26 **Integrating Genomics into Indonesia's National Health Survey: Technical Insights from the BGSI Central Biobank** *Ines Irene Atmosukarto, Ministry of Health of Republic Indonesia, Indonesia*
		14:26 - 14:38 **Viability Cryopreservation of Multiple Types of Tissues via a Novel Vitrification Platform Technology** *Yuansheng Tan, Servare Biotechnology Co., Ltd., China*
		14:38 - 14:50 **Scaling Newborn Screening and Biobank Integration for Early Child Health Interventions in South Africa** *Engela Helena Conradie, North-West University, South Africa*
		14:50 - 15:02 **Integrating an ISO 20387-Certified Biobank with a Comprehensive Clinical Database to Power Research in a Large Pediatric Liver Transplantation Cohort** *Xiaonan Kang, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, China*
		15:02 - 15:14 **Toward a Maturity Model: Foundational Findings for Evaluating Trusted Research Environments in Federated Analytics Networks** *Jasper Hoi Chun Luong, The University of British Columbia, Macao*
		15:14 - 15:26 **The World's Largest Germplasm Resource Bank for Wildlife has been Established in Guangdong Chimelong Group** *Guixin Dong, Chimelong Group Co., China*
		15:26 - 15:38 **The ISBER Mentoring Program, a New Online Resource for your Biobank Staff** *[Recorded Presentation]* *Marianne Henderson, National Cancer Institute, International Society for Biological and Environmental Repositories, USA* *Shonali Paul, CloudLIMS.com, India*
		15:38 - 16:00 **Q&A/Panel Discussion**

TUESDAY, APRIL 21, 2026

14:00 - 16:00
CONCURRENT
Functional Hall 2

Biospecimen Research - The Science Behind the Sample

CONTRIBUTED PAPER SESSION 4 - BIOSPECIMEN RESEARCH - THE SCIENCE BEHIND THE SAMPLE

Moderators: Engela Helena Conradie, North-West University, South Africa and Yuqing Ji, Huashan Hospital, Fudan University, China

14:00 - 14:02	**Introductions**
14:02 - 14:14	**Biospecimen Science: The Construction and Application of a Dual-Layer Theoretical Framework** *Weiye Charles Wang, Shanghai Biochip Center (SBC), National Engineering Research Center, China*
14:14 - 14:26	**Biobanking for Booroolongs: Investigating the Effect of Bovine Serum Albumin (BSA) and Caffeine on Post-Thaw Sperm Motility in a Threatened Frog Species** *Zara Melrose Anastas, University of Wollongong Faculty of Science Medicine and Health, Australia*
14:26 - 14:38	**Determination Of Biocontainment Levels For Biobanked Samples – A South African Case Study** *Puseletso Johnston, Agricultural Research Council, South Africa*
14:38 - 14:50	**A Comparative Evaluation of Different Cooling Strategies for Cryopreserving Mouse Liver Tissue: Assessing Viability, Structure, Metabolism, and Regenerative Potential** *Jinlian Pei, Medical Innovation Research Department of PLA General Hospital, China*
14:50 - 15:02	**Industry Clinical Trial Samples In Long-Term Storage: A Quality And Stability Study by Takeda Pharmaceutical's Biobank** *Shannon Chan, Takeda Development Center Americas Inc, USA*
15:02 - 15:14	**The GenV Biobank: Powering Biological Research in a Large Longitudinal Cohort of Australian Newborns and Their Parents** *Richard Saffery, Murdoch Children's Research Institute, Australia*
15:14 - 15:26	**Morphology-Guided Zonal Sampling Protocol for Colorectal Cancer: A Histology-Based Strategy to Enhance Biobank Specimen Quality** *Weiwei Jing, Fudan University Shanghai Cancer Center, China*
15:26 - 15:38	**Development of Advanced Vitrification Solutions through the Application of Macromolecules: A Case Study Using PVP** *Ruidong Ma, Northeastern University, University of Washington, USA*
15:38 - 16:00	**Q&A/Panel Discussion**

16:00 - 16:30
Exhibit Hall

Afternoon Networking Break

16:30 - 17:30
Functional Hall 1

People, Policy & Biobanking

ISBER CONTRIBUTED PAPER SESSION 5 - PEOPLE, POLICY & BIOBANKING

Moderators: Io Hong (Jack) Cheong, School of Public Health, Shanghai Jiao Tong University School of Medicine, China

16:30 - 16:32	**Introductions**
16:02 - 16:14	**Multiomics and Tumor Banking: A Comprehensive Platforms Integrating Cancer Diversity, Biomarker Discovery, and Personalized Cancer Care** *Abhishek Mohanty, HealthCare Global Enterprises Ltd, India*
16:14 - 16:26	**Streamlining Specimen Inventory Management at the NSW Health Statewide Biobank - A Five-Year Review** *Yingshi Li, New South Wales Health Pathology, Australia*
16:26 - 16:56	**BIO Journal Presentation** *Marianna Bledsoe, Biopreservation and Biobanking, USA*
16:56 - 17:30	**Q&A / Panel Discussion**

TUESDAY, APRIL 21, 2026		
17:30 - 19:00	Networking	**WELCOME RECEPTION, EXHIBITS & POSTER GALLERY WALK**
19:00		Shuttle bus leaves BGI
19:20		Shuttle bus leaves BGI
		Time to discover Shenzhen, China!

WEDNESDAY, APRIL 22, 2026		
7:15		Shuttle bus arrives at BGI
7:30 - 18:15 *Foyer Area*		Registration Desk and Speaker Services Open
7:30 - 8:30 *Room 411*	Networking	**SPEED NETWORKING ACTIVITY (REGISTRATION REQUIRED)** Hosted by Program Planning Task Force Members: Jelani Clarke, Henry Hong, and Wayne Wang If you are new to the ISBER meeting or a regular attendee, this is a great opportunity to meet new biobankers and discuss what is going on in your biobank specifically and the international biobanking community in general. Pre-Registration required. Meet your fellow delegates one on one in short, 5 minute increments Meet 10 or more delegates in this fun, interactive activity
8:30 - 8:45		Short break - delegates move to next rooms
8:30		Shuttle bus arrives at BGI
8:45 - 9:00 *Functional Hall 1*		**DAY 2 INTRODUCTIONS** *Jason Chen, Conference Co-Chair, China and Deb Leiolani Garcia, Conference Co-Chair, USA* *Welcome: Dr. Stella Somiari, President-Elect of the ISBER Board, USA*
9:00 - 10:00 *Functional Hall 1*	Bench to Biobank to One Health	**KEYNOTE LECTURE: TURNING BIOBANKS INTO CLINICAL ENGINES: PHARMA'S TRANSLATIONAL MEDICINE AND DIAGNOSTIC** *Dr. Su Xinying, MD, PhD, Development China, Pfizer, China* *Introduction by Dr. Stella Somiari, President-Elect of the ISBER Board* In clinical-stage drug development, translational medicine and diagnostics are pivotal for patient stratification, biomarker validation, and regulatory success. High-quality biobank samples linked to clinical and multi-omics data enable pharma to bridge discovery and application, reducing trial failure and accelerating precision medicine.Pharma-led integration of biobanking with translational medicine transforms biobanks into strategic engines for clinical development. This approach drives precision diagnostics, regulatory compliance, and patient-centric innovation.
10:00 - 10:30 *Exhibit Hall*		Morning Networking Break
10:00 - 19:45 *Exhibit Hall*		Exhibit Hall Open

WEDNESDAY, APRIL 22, 2026

10:30 - 12:00 CONCURRENT *Functional Hall 1*	Biospecimen Research - The Science Behind the Sample	**CONTRIBUTED PAPER SESSION 6 - BIOSPECIMEN RESEARCH - THE SCIENCE BEHIND THE SAMPLE** *Moderators: Yuqing Ji, Huashan Hospital, Fudan University, China and Dee McGarvey, Cooperative Human Tissue Network (CHTN), University of Pennsylvania, USA*	
		10:30 - 10:32	**Introductions**
		10:32 - 10:44	**A Resource of Paired CSF and Serum in Neuroimmune Diseases: Strategies for Micro-Volume Biospecimen Management** *Xiangjun Chen, Huashan Hospital Fudan University, China*
		10:44 - 10:56	**A Serum Metabolomics Signature for Early Detection and Molecular Stratification in Head and Neck Squamous Cell Carcinoma** *Hexin Ma, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China*
		10:56 - 11:08	**Integrated Antioxidant, Nanoparticle, and Antifreeze Protein Strategies Synergistically Enhance Cryotop Vitrification Outcomes of Porcine Parthenogenetic Embryos** *Xueming Zhao, Chinese Academy of Agricultural Sciences, China*
		11:08 - 11:20	**Iterative Orthotopic Mouse Models for Generating Phenotype-Defined Biospecimens and Matched Datasets in Hepatocellular Carcinoma Metastasis Research** *Kai Jiang, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, China*
		11:20 - 11:32	**Nationwide Genotype-Resistance Landscape of Wickerhamomyces Anomalus in China and Genomic Decoding of the First Pan-Resistant Clinical Isolate** *Tianshu Sun, Peking Union Medical College Hospital, China*
		11:32 - 11:44	**Living Biobanks of Liver Organoids: Valuable Resource for Drug Safety Assessment** *Shuyu Gong, Children's Hospital of Shanghai, China*
		11:44 - 12:00	**Q&A/Panel Discussion**
10:30 - 12:00 CONCURRENT *Functional Hall 2*	Bench to Biobank to One Health	**CONTRIBUTED PAPER SESSION 7 - BENCH TO BIOBANK TO ONE HEALTH** *Moderators: Louise Ludlow, Murdoch Children's Research Institute, Australia and Io Hong (Jack) Cheong, School of Public Health, Shanghai Jiao Tong University School of Medicine, China*	
		10:30 - 10:32	**Introductions**
		10:32 - 10:44	**Transforming Biobanking Operations: A Case Study on the Integration and Impact of a Fully Automated -80°C Storage System at the MUB Biobank** *Anna Michalska-Falkowska, Uniwersytet Medyczny w Bialymstoku, Medizinische Universitat Graz, Poland*
		10:44 - 10:56	**Advancing Regional Biobanking and Biosafety Governance in ASEAN: From Feasibility to Policy and Global Alignment** *Jasper Hoi Chun Luong, Smoke-Free and Healthy Life Association of Macau, Macao*
		10:56 - 11:08	**Development of the First National Human Biospecimen Proficiency Testing Program by the Thailand Biobank Consortium** *Natini Jinawath, Ramathibodi Comprehensive Cancer Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand*
		11:08 - 11:20	**Indonesia's Biobank Network for Precision Medicine and Population Genomics: First National Biobank Infrastructure** *Ines Irene Atmosukarto, Ministry of Health of Republic Indonesia, Indonesia*
		11:20 - 11:32	**From Data Fragmentation to Integration: Developing the Pathogenic Variant Database (CRDPVD) of the National Rare Disease Biobank of China** *Yiran Zhang, Peking Union Medical College Hospital, China*
		11:32 - 11:44	**Machine Learning-based Prediction of Antimicrobial Resistance in Klebsiella Pneumoniae Using Whole Genome Sequence Data** *Jingjia Zhang, Peking Union Medical College Hospital, China*
		11:44 - 12:00	**Q&A/Panel Discussion**

WEDNESDAY, APRIL 22, 2026

12:00 - 13:00 *Exhibit Hall*		General Lunch, Posters, and Exhibits
12:00 - 13:00 *Room 411*		DALs/RAs/Biobanking 101/201 working lunch (by invitation only)
13:00 - 14:30 CONCURRENT ***Functional Hall 1***	Biospecimen Research - The Science Behind the Sample	**E&T WORKSHOP 1: BIOBANKING: MEETING THE NEEDS OF DOWNSTREAM RESEARCH** This workshop explores how modern biobanking practices can better serve today's and future research needs. Aimed at biobank professionals, researchers, and managers, the session covers the full biospecimen lifecycle, from pre-analytical variables, collection workflows, quality assurance, data integration, and interoperability. Participants will learn how upstream biobank decisions influence downstream experimental reliability and compatibility with new analytical platforms. Through real-world case studies, the workshop highlights practical strategies to reduce research waste, enhance specimen and data integrity, and adapt operations to diverse research demands while maintaining ethical compliance and sustainability. Attendees will gain practical insights to align biobanking with evolving scientific demands and improve research outcomes. *Presenters:* *Anna Michalska-Falkowska, Medical University of Bialystok, Poland* *Zisis Kozlakidis, International Agency for Research on Cancer, World Health Organization, France*
13:00 - 14:30 CONCURRENT ***Functional Hall 2***	Bench to Biobank to One Health	**E&T WORKSHOP 2: INTEGRATION OF MULTI-OMICS AND MULTIMODAL DATA** This 90-minute workshop, Integration of Multi-Omics and Multimodal Data, proposed for ISBER 2026, focuses on practical strategies for integrating and standardizing high-throughput multi-omics and multimodal data. The session includes brief expert presentations on integration methods and real-world applications, followed by interactive polling and group discussions. Participants will share challenges, exchange experiences, and explore best practices for data harmonization, reproducibility, and translational research, concluding with key takeaways and future perspectives. *Presenters:* *Zou Xin, School of Medicine, Linyi University, China* *Zhang Zhen, Shanghai Ninth People's Hospital & College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Research Institute of Stomatology and Shanghai Key Laboratory of Stomatology, China*
14:30 - 14:45		Short break - delegates move to next rooms
14:45 - 15:45 CONCURRENT ***Functional Hall 1***	Smart Biobank: AI, Automation, Digitalization	**CONTRIBUTED PAPER SESSION 8 - SMART BIOBANK: AI, AUTOMATION, DIGITALIZATION** *Moderators: Shonali Paul, CloudLIMS.com, India and Jelani Clarke, AminoChain, Canada*
		14:45 - 14:47 — **Introductions**
		14:47 - 14:59 — **Implementing a Research-Driven, Fully Digital Biobanking System: Experience from the Second Affiliated Hospital Biobank, Nanchang University** *Yun Yi, The Second Affiliated Hospital of Nanchang University, China*
		14:59 - 15:11 — **Integrated Image Repository for Breast Tissue Biobank: Enabling Translational Research** *Madhura Kulkarni, Prashanti Cancer Care Mission Pune, India*
		15:11 - 15:23 — **Intelligent Biobank Supports the Construction of Shanghai Natural Population Cohort Project** *Ping Xiao, Shanghai Municipal Center for Disease Control and Prevention, China*
		15:23 - 15:35 — **Label-free Intelligent Assessment of Organoid Viability and its Applications** *Ruixin Yang, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, China*
		15:35 - 15:45 — **Q&A/Panel Discussion**

WEDNESDAY, APRIL 22, 2026

14:45 - 15:45 CONCURRENT *Functional Hall 2*	People, Policy & Biobanking	**CONTRIBUTED PAPER SESSION 9 - PEOPLE, POLICY & BIOBANKING** *Moderators: Dee McGarvey, Cooperative Human Tissue Network (CHTN), University of Pennsylvania, USA and William Schleif, Johns Hopkins All Children's Pediatric Biorepository, USA*	
		14:45 - 14:47	**Introductions**
		14:47 - 14:59	**Audit Update on Breast Tissue Biobank Set-up from a Single Institutional Cohort in an LMIC** *Laleh Busheri, Prashanti Cancer Care Mission, Prashanti Cancer Care Mission Pune, India*
		14:59 - 15:11	**Construction and Operation of the Biobank at Peking University People's Hospital: A Comprehensive Practice for Standardized Biomedical Resource Preservation** *Yujun Zhang, Peking University, China*
		15:11 - 15:23	**Returning Incidental Findings in Biobanking: Genes Identified and Return-to-Patient Procedures** *Priyanka Seenauth, University Health Network, Canada*
		15:23 - 15:35	**Construction of Patient-Derived Organoid-Based Living Biobank in a Gerenal Public Hospital: Key Strategies and Early–Stage Experiences** *Yi Zhang, Zhongshan Hospital Fudan University, China*
		15:35 - 15:45	**Q&A/Panel Discussion**
15:45 - 16:15	Afternoon Networking Break		
16:15 - 17:15 CONCURRENT *Functional Hall 1*	Smart Biobank: AI, Automation, Digitalization	**CONTRIBUTED PAPER SESSION 10 - SMART BIOBANK: AI, AUTOMATION, DIGITALIZATION** *Moderators: Julia (Huijie) Jiang, Huashan Hospital, Fudan University, China and Zach von Menchhofen, Cooperative Human Tissue Network (CHTN), University of Pennsylvania, USA*	
		16:15 - 16:17	**Introductions**
		16:17 - 16:29	**Distinctive Features on Building the Huashan Hospital Fudan University BioBank** *Jingsong Wu, Huashan Hospital Fudan University, China*
		16:29 - 16:41	**Database Construction Enabled by AI and its Application in Precision Diagnosis and Treatment** *Song Wu, South China Hospital Shenzhen University, China*
		16:41 - 16:53	**The Analysis of Ethical Issues in AI-Based Organoid Biobanks** *Chutian Huang, Children's Hospital of Shanghai, China*
		16:53 - 17:05	**Exploration and Reflection on the Construction of Unmanned Biobanks** *Wei Liang, Shanghai Clinical Research and Trail Center, China*
		17:05 - 17:15	**Q&A/Panel Discussion**
16:15 - 17:15 CONCURRENT *Functional Hall 2*	Innovative Technology in Biobanking	**CONTRIBUTED PAPER SESSION 11 - INNOVATIVE TECHNOLOGY IN BIOBANKING** *Moderators: Jelani Clarke, AminoChain, Canada and Shonali Paul, CloudLIMS.com, India*	
		16:15 - 16:17	**Introductions**
		16:17 - 16:29	**Enhancing Perceived Data Security in an In-House Developed Biobank Laboratory Information Management System: Insights from a Multi-Stakeholder Workshop** *Lutfan Lazuardi, Universitas Gadjah Mada, Indonesia*
		16:29 - 16:41	**Bridging the Automation Gap: A Benchmark Review and Modular Approach to Accessible Tube Handling in Biobanking** *Bernal Cortes, Labot, Costa Rica*
		16:41 - 16:53	**Establishing a U.S. Biobank Within a Global Network: Considerations for Aligning Legacy Human Samples to International Governance Standards** *Razan Humeida, AstraZeneca Pharmaceuticals LP, USA*
		16:53 - 17:05	**Establishing a Virtual Repository, the Biobank of the Future** *Daniel Kelly, ARK Repository, USA*
		17:05 - 17:15	**Q&A/Panel Discussion**

WEDNESDAY, APRIL 22, 2026

17:15 - 18:15 CONCURRENT *Functional Hall 1*	Innovative Technology in Biobanking	**E&T WORKSHOP 3: THE HIDDEN DANGERS OF SELECTING LONG-TERM STORAGE LABWARE** This workshop provides a rare, deeply practical look into how engineering principles can, and should, inform decisions about long-term storage consumables. Attendees will gain a practical framework for evaluating long-term storage labware, learn how small manufacturing variations translate into large operational risks, and understand how to incorporate engineering-grade assessments into procurement decisions. The workshop empowers biobanking and laboratory professionals to balance cost pressures with robust quality assurance, ultimately safeguarding sample integrity and advancing ISBER's mission of high-quality, reproducible biobanking practices. *Presenter: Leigh Carter, Azenta US Inc, Singapore*
17:15 - 18:15 CONCURRENT *Functional Hall 2*	**ROUNDTABLE DISCUSSIONS**	
	Smart Biobank: AI, Automation, Digitalization	**Innovating Biobanks for Spatial Transcriptomics Research** *Juhi Tayal, Rajiv Gandhi cancer Institute and Research centre, India*
	People, Policy & Biobanking	**Community-Centered Biobanking: Lessons from Global South Leadership and Adaptations for Pandemic Response** *Helen Storey, PATH, USA*
	Biospecimen Research - The Science Behind the Sample	**From Custodians to Catalysts: An Intensification Strategy for Academic Biobanks** *Zisis Kozlakidis, International Agency for Research on Cancer, World Health Organization, France*
	Bench to Biobank to One Health	**Building Stronger Biobanking Ecosystems Through Strategic Collaboration, Data Quality, and Real World Operations** *Sandra Nanyonga, Universite Cote D'Azur, France*
	People, Policy & Biobanking	**Defining the End-of-Life: Establishing a Framework for Biobank Collection Expiration** *Anna Michalska-Falkowska, Medical University of Bialystok, Poland*
18:15 - 19:45 *Exhibit Hall*	Networking	**EXHIBITS AND POSTERS NETWORKING RECEPTION**
19:30	Shuttle bus leaves BGI	
19:45	Shuttle bus leaves BGI	
	Time to discover Shenzhen, China!	

THURSDAY, APRIL 23, 2026

7:30 - 16:00 *Foyer Area*	Registration Desk and Speaker Services Open
7:15	Shuttle bus arrives at BGI
7:45	Shuttle bus arrives at BGI
8:00 - 8:30 *Functional Hall 1*	**JOINT WELCOME REMARKS** *Jason Chen, Conference Co-Chair, China and Deb Leiolani Garcia, Conference Co-Chair, USA* *ISBER Past-President: Dr. Dayong Gao, ISBER Past-President of the ISBER Board, USA*

8:30 - 9:15 *Functional Hall 1*

People, Policy & Biobanking

KEYNOTE LECTURE: THE CURRENT STATUS OF BIOBANKS AND DATA ELEMENTS IN CHINA

Dr. Hengjun Gao, National Engineering Research Center for Biochip Shanghai, China
Introduction by Dr. Dayong Gao, Past-President of the ISBER Board

Over the past two decades, biobanking in China has undergone a profound transformation—from fragmented, resource-oriented infrastructure to a standardized, regulated, and increasingly data-driven ecosystem. From 2007 to 2026, China established a comprehensive national framework for biobanking through successive milestones, including:

1) The Biobank Branch of the Chinese Medical Biotechnology Association (BBCMBA) played a critical role as both a "translator" and "accelerator" in bridging standards with practice
2) The development of industry and national standards, implementation of accreditation systems aligned with international norms ISO20387
3) Building a standardization engine centered on SAC/TC559, signaling full alignment with international standards
4) Establishing a biobank accreditation system based on ISO 20387 approved by the China National Accreditation Service for Conformity Assessment (CNAS)

This phase enabled the emergence of NSBAAA (National Standardized Biobank with Administrative Approval and Accreditation), laying a solid foundation for quality, compliance, and interoperability. Building upon this foundation, recent advancements (2024–2026) mark a critical shift toward biospecimen-related data as a core asset. Key breakthroughs include:

1)The creation of major disease data products and their successful listing on data exchanges
2)The establishment of trusted data spaces and national standards for data circulation and anonymization
3)The development of disease-specific large models and integrated data infrastructures
4)The realization of real-world data product transactions, signaling the emergence of a functional data market

These developments demonstrate that biobanks are no longer merely repositories of samples but are evolving into engines of data production and value generation. The changes represent the transformation from raw data to tradable value. In this context, the CBDTM paradigm (Clinical Biobank Data to Translational Medicine) is proposed as a new model for translational medicine. This paradigm emphasizes:

1) Converting clinical questions into structured, analyzable data,
2) Transforming biospecimens into high-value data assets,
3) Enabling data-driven productization and industrial translation, and
4) Bridging innovation and industrial chains for scalable impact. In conclusion, CBDTM, originated in China and envisioned for global adoption, is positioned as a leading paradigm for clinical translational innovation.

THURSDAY, APRIL 23, 2026

9:15 - 10:00 *Functional Hall 1* — People, Policy & Biobanking

KEYNOTE LECTURE: 10 YEARS OF BCNET: DRIVING GLOBAL COLLABORATION IN BIOBANKING

Dr. Zisis Kozlakidis, PhD, MBA, International Agency For Research On Cancer/World Health Organization, France
Introduction by Dr. Dayong Gao, Past-President of the ISBER Board

Over the past decade, the Biobank and Cohort Building Network (BCNet) has transformed the global landscape of biobanking by fostering cooperation, capacity-building, and shared expertise among low- and middle-income countries (LMICs). Established as an IARC/WHO initiative, BCNet arose from a clear need: to strengthen the infrastructure, quality, and governance of biobanks so that all nations—regardless of resources—can contribute to and benefit from biomedical research. Over ten years, the network has grown into a vibrant international community that bridges scientific, geographic, and economic divides.

BCNet's achievements are grounded in three pillars: training, standardisation, and partnership. Through targeted workshops, technical exchanges, and mentorship programmes, the network has empowered institutions to develop high-quality biospecimen resources aligned with international standards. This effort has helped harmonise procedures, improve data integrity, and enable cross-border studies that were previously out of reach for many LMIC researchers. In parallel, BCNet has provided a trusted platform for dialogue on ethics, governance, and equitable benefit sharing—critical elements for ensuring public trust and long-term sustainability.

A defining feature of BCNet's first decade is its emphasis on collaboration rather than competition. By connecting biobanks, research centres, ministries of health, and global partners, the network has catalysed joint projects on cancer research and population health. These collaborations have strengthened national research ecosystems and amplified LMIC contributions to global health innovation.

As BCNet enters its next decade, it stands as a model of how coordinated international action can build capacity, promote scientific equity, and accelerate discoveries that benefit populations worldwide.

10:00 - 15:15 *Exhibit Hall* — Exhibit Hall Open

10:00 - 10:15 *Exhibit Hall* — Morning Networking Break

10:15 - 12:15 *Functional Hall 1* — ALL TRACKS

MORNING SESSION

Session Chairs:
Dr. Cheong Io Hong, Hainan International Medical Center, Shanghai Jiao Tong University School of Medicine, China and
Deb Leiolani Garcia, Conference Co-Chair, ISBER

10:15 - 10:45	**Accreditation Practice for Biobanks in China** *Zhou Jie, China National Accreditation Service for Conformity Assessment, China*
10:45 - 11:15	**From Policy to Practice: Governance, Standardization and Operationalization of a Nationwide Biobank in Malaysia** *Dr. Kim Wee Ric, Ministry of Health Biobank, National Institutes of Health, Malaysia*
11:15 - 11:45	**From Cohort to Clinic: Advancing Precision Medicine in Vietnam through Biobanking and Organoid Technology** *Dr. Hanh Vu, Biobank, Pasteur Institute in Ho Chi Minh City, Vietnam; Vinmec Biobank, Hanoi, Vietnam*
11:45 - 12:15	**Building Interoperable Biobanks in Resource-Limited Settings: The Role of LIMS in Advancing Quality and Global Collaboration** *Dr. Lutfan Lazuardi, Universitas Gadjah Mada Bionark, Indonesia*

12:15 - 13:00 *Exhibit Hall* — General Lunch, Posters, and Exhibits

12:30 - 13:00 *Functional Hall 1* — People, Policy & Biobanking

GETTING TO KNOW ISBER

Whether you are new to ISBER, a long-time member or considering to become a member, join us in this session to learn more about the Society and to ask questions!

Engela Conradie, Centre for Human Metabolics, South Africa
William Schleif, Johns Hopkins All Children's Pediatric Biorepository, USA

THURSDAY, APRIL 23, 2026

13:00 - 14:00
Functional Hall 1

Biospecimen Research - The Science Behind the Sample

JOINT SESSION 1 - ORGANOIDS: PIVOTING THE LIVING BIOBANKS

Moderators: Dee McGarvey, Cooperative Human Tissue Network (CHTN), University of Pennsylvania, USA and Xiaoyan Zhang, National Engineering Research Center for Biochip Shanghai, China

Biobanks have long been an important platform for medical research, offering a vast repository of biospecimens, including tissues, body fluids, and biomolecules, to researchers. These repositories have played a pivotal role in advancing our understanding of diseases and developing novel therapies.

As technology continues to advance, traditional biospecimens are becoming insufficient to meet the demands of translational research. Living biobanks, particularly in the form of organoids, are garnering increased attention across various domains. Organoids are not static frozen biospecimens; rather they are living specimens that can be cultured making them invaluable for developmental biology, disease modeling, and drug discovery.

In this session our distinguished international panel will discuss some of the limitations and challenges from their regional perspectives when attempting to implement organoids in clinical practice and the pharmaceutical industry with a focus on global collaboration and best practices.

1. The scarcity of standardized organoid protocols hinders the broad implementation of standardization.
2. The variability in organoid quality and long-term maintenance requires more exploration.
3. Establishing standardized quality control systems for organoids from various organs is challenging,
4. Establishing international standards, whether for specific organoids or comprehensive organoid biobanks, should be undertaken through collaboration within an international expert alliance

13:00 - 13:12	**From Living Biobank to Functional Testing: Our Experience with an Automated and AI-Enabled Gastric Cancer Organoid Platform** *Jinguo He, National Engineering Research Center for Biochip Shanghai, China*
13:12 - 13:24	**Annotated Living Organoid Banking: a Framework for Bridging the Research Specimen Continuum** *V Krishnan Ramanujan, Cedars Sinai, USA*
13:24 - 13:36	**The Important Roles of Patient-Derived Organoids and Organoid Assembloids in Precision Medicine** *Yingyan Yu, Ruijin Hospital, Shanghai Jiaotong University, China*
13:36 - 13:48	**A Living Biobank of Patient-Derived Organoids: Advancing Life Science and Translational Medicine** *Jun Mei Zhou, Shanghai Children Hospital, China*
13:48 - 14:00	*Q&A / Panel Discussion*

THURSDAY, APRIL 23, 2026

14:00 - 15:00
Functional Hall 1

Smart Biobank: AI, Automation, Digitalization

JOINT SESSION 2 - AI-DRIVEN BIOBANKING: ENHANCING DATA INTEGRATION, DISCOVERY, AND PRECISION MEDICINE

Moderators: Weigang Li, National Engineering Research Center for Biochip Shanghai (Shanghai Biochip Co., Ltd.), China and Shonali Paul, CloudLIMS.com, India

The world of Biobanking is changing with Artificial Intelligence (AI). It is reshaping how biobanks operate, especially in their relationship with data. Biobanking is continually reshaped by emerging technologies, policies and societies expectations. While biobanks were defined as collections of samples and associated data, they are evolving into complex centers for both data and samples.

This session will discuss how AI utilization in biobanking is currently seen as fragmented and institution-specific in nature. It will also include views from our accomplished speakers that the need for harmonizing international regulations and best practices emphasizes the lack of global guidelines for AI use in biobanking, ensuring ethical considerations and compliance with legal and technical compliance.

Our four distinguished speakers will address the following from their regional perspectives (U.S., EU, and China) with a focus on cross-border collaboration and best practices as this would provide valuable insight as to how regions handling regulatory issues:

1. The current state of AI utilization in biobanking from the speakers' perspectives (US, EU (AI ACT, include work with BCNet), and China) with a focus on cross-border collaboration and best practices.
2. Are we ready? What are the challenges? AI compliant - harmonization of international regulatory issues including technology, legal, ethical and governance
3. Next steps - development and implementation of guidelines (Best Practices) - a call for action to collect and share case studies from around the world.

14:00 - 14:12	**AI in Biobanking from an EU perspective: Leveraging AI for the Next-Generation Biomedical Research** *Dr. Zisis Kozlakidis, International Agency For Research On Cancer/World Health Organization, France*
14:12 - 14:24	**How Intelligent Pathology Impact Morphological Quality Assessment During Tissue Sample Distribution** *Menghong Sun, Fudan University Shanghai Cancer Center, China*
14:24 - 14:36	**Capability Enhancement Framework for Large Language Models for Specialized Domains and its Applications** *Weidong Yang, Fudan University, China*
14:36 - 14:50	**Incorporation of AI into Biobanking Workflows and Operations** *Gregory Grossman, Advancing Sight Network/Precision Ocular Biobank, USA*
14:50 - 15:00	**Q&A / Panel Discussion**

15:00 - 15:15
Exhibit Hall

Afternoon Networking Break

THURSDAY, APRIL 23, 2026

15:15 - 16:15
Functional Hall 1

Smart Biobank: AI, Automation, Digitalization

JOINT SESSION 3 - DATA DRIVEN BIOBANKING: FROM BIOSPECIMEN STORAGE TO DIGITAL CAPABILITY, DATA PRODUCTS, AND COMPLIANT CIRCULATION

Moderators: Julia (Huijie) Jiang, Huashan Hospital, Fudan University, China and Charles W. Wang, National Engineering Research Center for Biochip Shanghai, China

Biobanks worldwide are rapidly expanding their collections of biospecimens, yet the scientific value generated from these resources remains uneven and often limited. This gap reflects a fundamental challenge: biobanking should no longer be evaluated solely by the scale of biospecimen storage, but by its capacity to generate high-quality, reusable, and trustworthy data.

This session is grounded in the dual-layer theoretical framework of biospecimen science we have developed, which conceptualizes biobanking as the interaction between a scientific layer – where biospecimens are transformed into evidence through research – and an engineering layer – where biobanks function as systems capable of producing, managing and governing data.

Through short framework presentations and moderated discussion, this session aims to develop shared conceptual understanding and consensus principles that support sustainable, trustworthy, and internationally interoperable data-driven biobanking.

15:15 - 15:30	**Data-Driven or Data-Drowning? Navigating the Lifecycle of the Digital Biospecimen while not Losing Your Metadata** *Zach von Menchhofen, Cooperative Human Tissue Network (CHTN), University of Pennsylvania, USA*
15:30 - 15:45	**The Biobank-to-Bedside Continuum: Building High-Quality Cancer Cohorts for Clinical Research** *Haixin Li, Tianjin Medical University Cancer Institute and Hospital, China*
15:45 - 16:00	**Biospecimen-Driven Approach: From Clinical Questions to Data Products** *Charles W. Wang, National Engineering Research Center for Biochip Shanghai, China*
16:00 - 16:15	**From Samples to Insights: Biobanking and Data Sharing in the Global Research Landscape** *Dr. Stella Somiari, Windber Research Institute, USA*

16:15 - 16:30
Functional Hall 1

JOINT CLOSING REMARKS

Dr. Stella Somiari, President-Elect of the ISBER Board, USA and Charles W. Wang, National Engineering Research Center for Biochip Shanghai, China

16:45 Shuttle bus leave BGI, heading to the Red Lantern Celebration

16:45 Shuttle bus leave BGI, heading back to the hotels

17:00 - 20:50

Networking

THE RED LANTERN CELEBRATION (REGISTRATION REQUIRED)

Location: Offsite

21:15 Shuttle bus leaves the venue, heading back to the hotels

Keynote Lecturers

DR. HENGJUN GAO

MD, PhD, National Engineering Research Center for Biochip Shanghai, China

Dr. Hengjun Gao is a distinguished gastroenterologist at the Shanghai Jiaotong University School of Medicine in 2001. He established and is the director of the National Engineering Center for Biochip at Shanghai with a total investment of 290 million RMB by the National Development and Reform Commission since 2001. He is the director of both the Shanghai Center for Molecular Medicine, and the Data Innovation Center for Major Disease of Shanghai Data Exchange. Dr. Gao is also the Chairman of the National Technical Committee on Bio-specimen of Standardization Administration of China (SAC/TC 559), Chairman of the Biobank Branch China Medicinal Biotech Association (BBCMBA), Chairman of the Industry-Academia-Research Translational Medicine Branch of the Chinese Anti-Cancer Association, and President of the Chinese Biobank Alliance.

PROF. CHEN WAN-TAO

MD, PhD, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China

Prof. Wan-Tao Chen serves as President of the Shanghai Institute of Stomatology and as Deputy Chair of the Department of Oral and Maxillofacial Surgery at Shanghai Ninth People's Hospital. He also leads the Shanghai Professional Technical Service Platform-Sharing Platform for the Tissue Sample and Bioinformatics Database of Oral Cancer. His clinical and research expertise is centered on cancers, with a specialized focus on establishing and application biobank of head and neck cancer. As a principal investigator, he has secured substantial competitive funding, including 14 national and international grants. He has published over 110 papers in internationally renowned professional journals.

DR. SU XINYING

MD, PhD, Development China, Pfizer, China

Dr. Xinying Su is an accomplished leader in translational medicine, specializing in bridging scientific innovation with clinical application to accelerate drug development and improve patient outcomes. With extensive experience in diagnostics and precision medicine, Dr. Su drives strategies that integrate biomarker research, clinical trial design, and regulatory compliance to support drug development. Dr. Su holds an MD from Shanghai Jiao Tong University and a PhD in Oncology from Paris 7 University , with 30+ publications in translational and clinical diagnostics.

DR. ZISIS KOZLAKIDIS

PhD, MBA, International Agency For Research On Cancer/World Health Organization (IARC/WHO), France



Dr. Zisis Kozlakidis is the Head of Laboratory Services and Biobanking at the International Agency for Research on Cancer, World Health Organization (IARC/WHO). He is responsible for one of the largest and most varied international collections of clinical samples in the world, focusing on gene - environment interactions and disease-based collections, and director of the LMIC-focused Biobank and Cohort building network. These WHO infrastructures support multinational research efforts in making treatments possible and delivering those to resource-restricted settings.

Posters

Search a poster by track, then by ID.

ID	TRACK	ABSTRACT TITLE	PRESENTER	COUNTRY
PB-14	Bench to Biobank to One Health	Biobank network in Japan to accelerate progress towards genomic medicine	Soichi Ogishima	Japan
PD-04		Genomic insights into environmental Hafnia paralvei antimicrobial resistance and virulence	Lee-Hendra Elvida Chenhaka	South Africa
PE-29		Integrated Serum Metabolomics Reveal Distinct Metabolic Reprogramming anda Novel Diagnostic Classifier in Colorectal Signet Ring Cell Carcinoma	Hu Shiqi	China
PE-30		Simple and Efficient Methods for Extracting High Quality and Quantity of High-Molecular-Weight Genomic DNA from Archived Frozen Tissues	Cong Zou	China
PG-08		An Ultra-rapid Cooling-warming Platform Based on Copper-based Mesh Magnetothermal Cryotubes Enables Vitrification Cryopreservation of Mouse Ovaries	Conghui Tian	China
PB-03	Biospecimen Research: The Science Behind the Sample	Balancing Scientific Utilization and Biosafety: Management Protocols for a Hospital-Based MDR Bacteria & Bacteriophage Resource Biobank	Wei Zhang	China
PB-10		Impact of Alcohol Type on FFPE Block Quality for Immunohistochemistry	Shaji Ayillath Keezhadath	India
PC-02		A Lean Biobank for Pandemic Response: Maximizing Research Utility Via Case-Ascertained Enrollment in the Valido Study	Bernal Cortes	Costa Rica
PC-03		Balancing Value Realization and Risk Governance: A Fine-Graded Management Framework for Biospecimen	Xiaoyan Li	China
PE-03		Comprehensive Human Cerebrospinal Fluid Proteome and Lipidome Profiles Cross Approximately 70-year Lifespan Uncover Brain Aging Trajectories and Features	Haitao Sun	China
PE-10		Impact of Freezer Storage Duration on the Diagnostic Performance of Plasma p-tau181 and p-tau217 in Differentiating Clinical Stages of Alzheimer's Disease: A Cross-Sectional Study	Lifang Zhao	China
PE-11		Implementing an Autopsy Program: A Multidisciplinary Approach in HIV and Cancer Research	Larissa Oliveira Amorim	Brazil
PE-12		Investigation into the Quality and Integrity of Stored Biospecimen at the Biobank of the National Health Laboratory Service(NHLS)	Bonginkosi Duma	South Africa
PE-13		In vivo comparison of the anti-snake venom activity of the honey-derived phenolics and polyvalent antivenom	Aswad Khan	Pakistan
PE-14		Mechanistic Study of Bruceantin-Induced Apoptosis in HBV-Related Hepatocellular Carcinoma through Inhibition of the HBx/c-Myc/RPL27A Axis Supported by Biobank Resources	Jufang Huang	China
PE-15		Multiplexed Antibody-panel Based Quality Control Workflow For Biobanked Tissues	Yi Zhang	United States
PE-16		Optimized Protocol for Isolation and Characterization of Tumor-Educated Platelets for Liquid Biopsy Applications	Isabela Cristina de Souza	Brazil
PE-19		Optimizing RNA Quality in Cryopreserved Tissues without Preservatives: Impact of Preservatives, Thawing Methods and Tissue Aliquot Sizes	Kaiyu Qian	China
PE-20		Preserving Precision: Tailored Biobanking Strategies for Infectious Disease Specimens and Associated Clinical Annotations	Chao Xia	China
PE-21		Quality Control Of Distributed Biospecimens: A Two-Year Audit Linking Sample-Level QC To Clinical Metadata In A Colorectal Cancer Biobank	Yanzi Gu	China

ID	TRACK	ABSTRACT TITLE	PRESENTER	COUNTRY
PE-22	Biospecimen Research: The Science Behind the Sample	Significant Enhancement of Yield and Purity in Genomic DNA Extraction from Peripheral Blood Using an Optimized Magnetic Bead-Based Elution Protocol	Fei Ding	China
PE-23		Systematic Impact Of Repeated Freeze–Thaw Cycles On Pancreatic Cancer Tissue Quality: RNA Vulnerability And Histomorphological Changes	Guangqi Qin	China
PE-24		The Epigenetic Mechanism by Which GATAD2A Degradation Sustains KRAS Expression in Head and Neck Squamous Cell Carcinoma	Mi Zhang	China
PE-27		Thymosin Beta 10 Promotes Cancer Stemness and Malignant Progression in Head and Neck Squamous Cell Carcinoma	Xinran Zhao	China
PE-28		Uncovering the Translational Landscape of Ovarian Cancer: Insights from Profiling of Clinical Biospecimens	Yiying Chen	China
PE-32		A Novel Low-Toxicity Cryopreservation Strategy for Mouse Oocytes via Electroporation-Mediated Intracellular Trehalose Delivery	Menghan Wang	China
PG-04		Phosphorylation of PHLDA2-S42 Regulates Ferroptosis under Metabolic Stress through ALOX12-Mediated Lipid Peroxidation	Qingqing Wan	China
PG-03		On-Demand Organoid Construction from Cryopreserved Tissue Archived Blocks for Gastrointestinal Cancers	Qi Wang	China
PG-06		Urine Cancer Cells and PD-L1 as a Potential Non-Invasive Biomarker and a Living Biobank for Immune Checkpoint Inhibitor (ICI) Therapy in Bladder Cancer	Xuefeng Liu	United States
PG-07		Viability cryopreservation of multiple types of tissues via a novel vitrification platform technology	Yuansheng Tan	China
PG-09		Static Magnetic Field Combined with L-Proline Promotes Cryopreservation of Retinal Organoids by Inhibiting Adverse Stresses	Xiaohu Wang	China
PJ-02		Assessing Processing Time and Cell Count Performance as Fit-For-Purpose QC Metrics for PBMC Biobanking	Alejandra Helena Rangel	Australia
PJ-04		Long-Term Assessment of RNA Extracted from Lymphocytes Preserved in Triazole Compared with RNA Extracted from Buffy Coat Stored at –80°C	Marwa Saady	Egypt
PJ-05		Minimizing Pre-Analytical Variables on Peripheral Blood Mononuclear Cell (PBMC) Processing and Cryopreservation for Quality Improvement in Ramathibodi Comprehensive Tumor Biobank	Thanastha Thanomchard	Thailand
PJ-06		Quality Assessment of RNA Extracted from Fresh Tissue and Buffy Coat	Abrar Ramadan Abd Elkader	Egypt
PJ-07		Stability of DNA and RNA Concentration and Purity of Buffy Coat Samples from CLL Patients After One Year of –80°C Storage	Abrar Mohamed Ramadan	Egypt
PH-02	Innovative Technology in Biobanking	Bridging the Gap from Operational Function to Accreditable Quality: Implementation of a Unified Quality Management System Driven by Automated Processes and Digital SOPs at the MUB Biobank	Anna Michalska-Falkowska	Poland
PH-03		Construction and Clinical Application of SPDOs Organoid Cell Lines for Gastric Cancer	Yingyan Yu	China
PH-04		Cryogenic Technology: From Broad Applications in Life Sciences to Cutting-Edge Practices in Biological Sample Preservation	Yuqing Han	China
PH-05		DCLK1+ inflammatory CAFs define a poor-prognosis IM1 program underpinning perineural invasion in gastric cancer	Shizheng Xiong	China
PH-06		Emerging Fluorescence Technologies For Empowering Biospecimen Science Research in Biobanks	V Krishnan Ramanujan	United States
PH-07		Empowering the Optimization of Scientific Research Resources: Construction and Application of a Cost Accounting Model for Biological Samples	Yueyao Chen	China
PH-09		Experience in Establishing Patient-Derived Organoid Models of Gynecologic tumor	Qiaoxiu Gu	China

ID	TRACK	ABSTRACT TITLE	PRESENTER	COUNTRY
PH-10	Innovative Technology in Biobanking	Metabolic Programming of Tumor-Associated Macrophages Promotes T Cell Exhaustion in Uveal Melanoma	Haiyang Yu	China
PH-11		Optimization of Whole-Mount Autofocusing SMALDI Mass Spectrometry Imaging for Spatially Resolved Lipidomic Profiling of Patient-Derived Organoids	Chunyan Lan	China
PH-13		Technical Standards and Specifications for Establishing a Primary Oral and Maxillofacial Tumor Cell Bank via Conditional Reprogramming	Ming Yan	China
PH-14		Translating Human Intent into SQL: A Case Study of a PHP-based AI Bridge in an Academic Biorepository	Zachery von Menchhofen	United States
PI-01		65 degree Short-Term Heating: A Method for Transporting Urine Samples Over Long Distances Without Cold Chain	Youhe Gao	China
PI-03		AI–Enhanced Single Mode Electromagnetic Resonant Rewarming Technology for Optimal Cryopreservation and Biobanking	Wenzhao Wang	United States
PI-04		An Optimized and Automated Platform for High-Quality PBMC Isolation: A Comprehensive Evaluation of Standardized Methods with Integrated Plasma Collection	Di Li	China
PI-05		Optimizing FFPE Storage For The Future: Improving Space Utilization, Sample Integrity, And Traceability Through High-Density Automated Storage	Razan Humeida	United States
PI-06		The Gatway to Biological Research. BioOne!	Kyoungsoo Ha	Korea (the Republic of)
PA-01	People, Policy, and Biobanking	The Role of a 24/7 Monitoring and Alarm System in Safeguarding a Biobank	Sze Wai Lau	Hong Kong
PA-06		Construction of Risk Management System in Biobanks of General Hospitals in China	Xin LI	China
PB-01		Aier Eye Biobank: A National Distributed Network for Ophthalmic Genetic Resources	Min Li	China
PB-02		Australasian Biospecimen Network Association: Building A Network To Promote Outreach And Empower Research Innovation	Louise E Ludlow	Australia
PB-04		Biobank Performance And Research Alignment At Fudan University Shanghai Cancer Center: A Five-Year Institutional Audit (2020–2024)	Beiyan Liu	China
PB-06		Construction and Management of Women and Children Biobank in Fujian Province,China	Aizhu Lin	China
PB-07		Construction of Biobank in Xi'an People's Hosptial (Xi'an Fourth Hospital)	Zhanglin Zhang	China
PB-11		The Biobank of Shenzhen Third People's Hospital	Haiyan Wang	China
PB-12		The Children's Cancer Centre Biobank – A Catalyst For Collaboration	Louise E Ludlow	Australia
PB-13		The Construction and Application of TianTan Biobanks in Precision Medicine Research for Cerebrovascular Diseases	Jinxi Lin	China
PC-01		Advancing Reference Standards and Countermeasures for Pandemic Response: Development of and Lessons Learned from the Biospecimen Sourcing Initiative	Helen Storey	United States
PC-04		Biobank Driven Approach to Elucidation of Health And Disease Drivers in African Populations: BioAtlas Case Study	Jumi Popoola	Nigeria
PC-06		Biosafety Management of Infectious Samples in a Comprehensive Hospital Biobank	Genming Liu	China
PC-07		Bridging the Gap: Established Biobanks as Catalysts for Emerging Initiatives	Kashif Asghar	Pakistan

ID	TRACK	ABSTRACT TITLE	PRESENTER	COUNTRY
PC-09	People, Policy, and Biobanking	De la Mémoire Biologique à la Science du Futur : L'héritage de la Biobanque de l'IRESSEF	Souadou Ndoye	Senegal
PC-11		From Vision to Reality: Challenges In Developing Biobanking Capacity in Pakistan	Asim Farooq	Pakistan
PC-13		Strengthening Thailand's Cancer Research Ecosystem: A Decade of the Ramathibodi Comprehensive Tumor Biobank	Chawanit Wongkasa	Thailand
PC-14		BCNet: The Way Forward— Education, Digitalisation and Regional Collaboration for a Resilient Global Biobanking Ecosystem	Zisis Kozlakidis	United Kingdom
PC-15		The Hong Kong Science and Technology Parks Corporation (HKSTP) Biobank and Histopathology Services (BHS): Enabling Research Through Strategic Support	Victor Ma	Hong Kong
PD-01		Challenges in Developing Ethics-Based and Species-Specific Frameworks for Ensuring Integrity in Live Animal Biobanking	Se-hee Choe	Korea (the Republic of)
PD-03		Veterinary Biorepository: Importance of Standardization, Biosafety, Biosecurity, And Data Management	Puseletso Johnston	South Africa
PE-07		Establishing a High-Quality, Large-Scale Specialized Biobank for Cardio-Thoracic Diseases: Experience from Tianjin Chest Hospital, China	Jing Gao	China
PE-08		Establishing a Tumor Biobank Enhanced By Digital Pathology and A.I. in Developing Countries: CNC Pathlab Case Study	Aditya Saini	India
PF-02		Exploring Healthcare Students' Awareness and Sentiments Towards Biobanking	Marta A Ambrozewicz	United States
PF-03		Hearkening to the Voice of the Research Participants at MRC/UVRI and LSHTM Uganda Research Unit Biobank	Flavia Kisakye	Uganda
PF-05		The Mathison Centre Neurogenetics Biobank and Advancing Precision Mental Health	S-M Shaheen	Canada
PG-01		Exploring a Shared Ecosystem for Biobanks in Chinese Research Hospitals: A Collaborative Innovation Model Based on Blockchain and Smart Contracts	Kai Jiang	China
PJ-01		A Project Management Platform for Managing Quality Assurance Issues	Lyndsey Gonzales	United States
PJ-03		Effect of Pre-analytical Factors on Nucleic Acid from Formalin-Fixed, Paraffin-Embedded Tissue (FFPET) Samples: A Thailand Multi-Center Study	Chayanist Songpatanasilp	Thailand
PA-02	Smart Biobank: AI, Automation and Digitization	Automation-Driven Improvements in Biobank Workflow and Data Quality	Hoi Ying Siu	Hong Kong
PA-03		Sample Preprocessing Integrated Automated Equipment Patent R&D Plan	Jian Liu	China
PA-04		Data-Driven Optimization of Alarm Management in a Biobank Monitoring System	Qinqin Hou	China
PE-25		The Real-world Construction of An Information Manaagement Practice for a Research-oriented Biobank	Qi Qi Zhang	China
PE-26		The Role and Management Practices of Biobank in the Development of an Integrated Artificial Intelligence-Driven Information Platform for Lung Cancer Diagnosis and Treatment	Jing Gao	China
PA-05		Harmonized Blood Quality Assurance Metrics for Automated Biobanks	Cailin Climer	United States
PB-05		Building a TCM-Featured, AI-powered Biobank by Integrating Samples and Digital Data as Bioresources for Standardized Research and Clinical Translation	Ziran Zhao	China

Exhibitors Listing

Agilent Technologies 安捷伦科技有限公司 C30

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom.

Askion GmbH C31

ASKION is a global leader in medical technology, bioanalytics and optical sensors. With four core business units: biobanking, OEM solutions, fluorescence microscopy and laser rangefinders. We deliver one-stop development, manufacturing and customization, from concept to mass production, with premium technical expertise and scalable, tailor-made solutions. Our modular, customizable C-line® systems ensure permanent cooling chain and full traceability for automated cryogenic sample storage.

Azenta Life Sciences C10 / C11

Azenta Life Sciences is a leading provider of life sciences solutions worldwide, enabling life science organizations to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across drug development, clinical research, and advanced cell therapies for top pharmaceutical, biotech, academic and healthcare institutions globally.

Biozy Life Sciences Technology (Jiangsu) Co., Ltd 江苏臻远生物科技有限公司 C25

Biozy Biotechnology is dedicated to innovation and quality in life sciences.With a Class 100,000 clean workshop, automated manufacturing capabilities and a strongR&D team, we deliver integrated solutions for sample storage, addressingsmart coding, safety storage and seamless traceablity, supportingbiopharmaceuticals, clinical research, compound libraries, and biobanks worldwide

CRYO BIO SYSTEM C06

Cryo Bio System was established in 1987 as a subsidiary of IMV Technologies Group, specializing in the human health sector. The company is dedicated to life sciences and biodiversity conservation, aiming to provide researchers and medical professionals with innovative, high-security products that leverage IMV Technologies' expertise in the cryopreservation of biological samples. Its main areas of service include:

- Biobanking and epidemiological research
- Transfusion medicine and blood safety monitoring
- Cell culture and gene therapy institutions
- Pharmaceutical industry
- Assisted reproductive technologies
- Genomics and proteomics
- Forensic evidence storage
- Military medicine
- Biodiversity (conservation of animal and plant genetic resources)

Cryo Bio System operates in over 80 countries worldwide. Through its five subsidiaries located in the United States, India, Italy, the Netherlands, and China, as well as an efficient distribution network, the company consistently focuses on product quality, stays closely attuned to customer needs, and optimally meets various professional requirements.

Cryotherm GmbH & Co.KG C22

Cryotherm, based in Germany, manufactures vacuum super-insulated vessels and transfer lines for cryogenic gases like helium, nitrogen, oxygen, argon, and hydrogen. Our applications include biobanking, cryopreservation, gas storage and transport, transport cooling systems, and advanced cryogenic control technology. We offer complete solutions from planning and manufacturing to installation, including custom systems such as multi-channel helium pipes, cooling baths, closed-loop systems, valve boxes, storage tanks, and transport vessels for small trucks. Our comprehensive after-sales service includes a 24/7 hotline, service contracts, training, commissioning, and IQ/OQ qualification to support customers throughout the entire lifecycle of their cryogenic systems.

GALLOPSTEED SCI-TECH CO.,LTD 骅川(上海)科技有限公司 C08 / C09

Huachuan (Shanghai) Technology Co., Ltd. is a technology-driven enterprise that has long been dedicated to the research, development, production, and sales of various cutting-edge biological and medical devices. Its products, which feature independent brands and intellectual property, have been widely acclaimed. Notably, its new generation pneumatic intelligent laboratory sample transfer and storage management system, with its innovative design and unique technological measures, responds to the national call for carbon peaking and carbon neutrality, perfectly solving pain points such as high energy consumption, stringent facility requirements, and significant biological exposure risks in various biomedical institutions. Since its launch, it has received broad recognition from experts and professionals within the industry.

Genepoint Technologies A05

Genepoint Technologies is committed to providing innovative, automated and comprehensive storage solutions for biological samples. Our independent R&D and in-house production ensure full process control, delivering more stable products and reliable services.

Upholding the mission of "Inspire Life Exploration", Genepoint consistently pushes technological boundaries of automated sample storage and advances the practical applications of life sciences and biomedicine through ongoing innovation.

Genepoint is headquartered in Shanghai and has production, R&D, and product operation centers in both China and Singapore.

Haier Biomedical 海尔生物医疗 A02

Haier Biomedical was established in 2005 and listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in 2019 (stock code: 688139). The Company aims to create the best user experience for a wide range of user groups such as hospitals, biotechnology enterprises, universities & colleges, scientific research institutions, centres for disease control and prevention, plasma stations, and primary public health authorities. The Company mainly engages in two major business fields: life sciences and medical innovation.

Jiangsu SERLNG New Energy Technology C32 / C33

SERLNG is dedicated to providing engineered cryogenic products and services in the industrial gas, life sciences and green energy markets. We are committed to customers by providing broad product lines, advanced technologies and continuous innovation.

As our company name indicates, we want to be GREEN in all our endeavors, and embed ESG in our ecosystem.

Liconic C27

World leader in automated storage technologies for Biobanking, Cell Culture, Chemistry, Compound Screening, and Assay development and testing. Automated storage solutions from -200C to +200C.

LVL technologies GmbH & Co. KG — C34

LVL technologies GmbH & Co. KG has been offering consumables for laboratory automation and automated liquid handling since 1986. The focus of our product range is sample storage solutions in standardized SBS format. We have specialized our product portfolio in the 2D SAFE® Tube Rack System available in several different volumes from 200µl up to 8ml and rack types 96/48/24 SBS format. The associated infrastructure, such as readers, cappers and useful extras are also part of our range.

MGI Tech Co., Ltd. 深圳华大智造销售有限公司 — C07

MGI Tech Co., Ltd. is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries.

MVE Biological Solutions — C01 / C02

MVE Biological Solutions is the global leading manufacturer of cryogenic storage and shipping devices. For over 60 years, we set the standard for storing biological materials at low temperatures. MVE is the preferred brand for cryogenic equipment in various application areas, including biopharma, cell and gene therapies, storage of cord blood and stem cells, medical research facilities, government institutions, IVF centers, hospitals and clinics, and animal husbandry and livestock.

Nexpring Health — C15

Nexpring Life Sciences helps laboratories and breeding operations standardize their most critical workflows - analysis, culture, and cryopreservation - to improve outcomes, reduce variability, and operate with confidence.

Our portfolio includes Chang cytogenetics media, CASA systems for animal breeding and research, controlled-rate freezers for cord blood and CGT applications, and specialized research workflow equipment such as IVFTech flow hoods. All solutions are supported by expert applications guidance, comprehensive training, and a disciplined service model that ensures reliability from bench to biobank.

Peak Scientific Instruments Shanghai Ltd (Noblegen Cryogenics) 毕克气体仪器贸易(上海)有限公司 — C29

Noblegen designs, manufactures, and supports high-performance liquid nitrogen generators, providing a reliable and cost-effective solution for liquid nitrogen applications worldwide. We serve a variety of industries from research, IVF, MRI, animal husbandry, pharmaceutical, cryogenics and more.

Origincell — A01

Orcella Instruments specializes in cutting-edge R&D and manufacturing of intelligent, fully automated cryogenic and ULT biobanking systems. Equipped with advanced research platforms and cutting-edge laboratories, Orcella cultivates cross-disciplinary collaboration, delivering groundbreaking solutions designed to meet the diverse needs of biobanks across different temperature zones, sample formats, and scales.

Hisense

Qingdao Hisense Commercial Cold Chain Co., Ltd. 青岛海信商用冷链股份有限公司 A06

Qingdao Hisense Commercial Cold Chain Co., Ltd. is a wholly-owned subsidiary of Hisense Group that focuses on the health sector, specializing in the research and development, production and sales of automated storage equipment, automated blood banks and vaccine banks, laboratory automation equipment and biological sample information management systems. The company has a national-level R&D center, professional laboratories, an internationally leading automated equipment production line and a global service network, and is committed to providing high-end products and considerate services to users worldwide. The company's products are widely used in medical institutions, disease control centers, universities, research institutes, blood centers, customs quarantine, biopharmaceutical enterprises and many other institutions.

Relying on Hisense Group's over 50 years of expertise in refrigeration technology and years of experience in automated manufacturing, the company has built a high-quality R&D team, and its product system covers a wide range of application scenarios including intelligent storage of biological/compound samples, cell and gene therapy, high-throughput drug screening, inspection and quarantine, etc., continuously leading the technological upgrade and intelligent transformation of domestic automated equipment and software.

SERVARE

Servare Biotechnology(Ningbo) Co., Ltd. 赛维尔生物科技（宁波）有限公司 C28

Servare Biotech specializes in cutting-edge, next-generation vitrification cryopreservation technology. Committed to the preservation of functional biological activity, the company offers a transformative R&D paradigm for the pharmaceutical industry, innovative research tools for scientific exploration, and a foundational platform for the storage and utilization of precious biological resources.

With our proprietary platform technologies, Servare has developed an integrated solution including reagent formula, intelligent equipment, and technical services. It is currently the only commercial entity in the world capable of achieving vitrification-based viable preservation at the cellular, tissue, and organ levels—positioning Servare as a global leader in the field.

iKelvin 艾尔温

Shanghai iKelvin Life Science & Technology Co., Ltd 上海艾尔温生命科技有限公司 A03

iKelvin Life Sciences was founded in 2020 as a high-tech enterprise specializing in AI-powered laboratories/biobanks within the life sciences sector. It is a leader in the field of domestically developed and original scientific research instruments, focusing on cryogenic and optical technologies. Through disruptive innovation, the company has broken international technological monopolies. Dedicated to the R&D, production, sales, and full-process services of life science laboratory/biobank-related equipment, iKelvin has forged a dual-drive business model centered on "disruptive product innovation and transformative service innovation."

B °Cryo Systems

Sichuan B Cryogenic Systems Co., Ltd. 四川贝纳吉低温设备有限公司 C13 / C14

B Cryogenic is dedicated to provide innovative cryogenic preservation solutions to meet the high standard of life science applications. The product lines include: controlled-rate freezer, vapor cryogenic freezer, automatic cryogenic freezer, aluminum liquid nitrogen container, dry shipper, vacuum pipeline and cloud-based monitoring system. B Cryo System, your trusted partner for cryogenic preservation.

SpecieBio
BioExchange: Where Science Meets Access

Specie Bio C03

Founded by scientists, technologists and serial entrepreneurs, Specie Bio's mission is to harness the potential of all untapped multimodal health data and samples to accelerate clinical R&D. Specie Bio has established a global provider partner network with leading hospital systems, medical centers, and research institutions. Our AI-matching engine (BioExchange) helps biopharma and life science researchers (including top Pharma/CROs) find and access clinical-data-linked specimens and multimodal data on-demand across our provider network. Specie Bio helps provider partners expand visibility of their inventories, enhance collaboration efficiency with researchers, and grow a sustainable source of funding while accelerating their mission to enable R&D.

Thermo Fisher Scientific — C04 / C05

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.

Our global team delivers an unrivalled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Zhejiang Sorfa Life Science Research Co., Ltd. 浙江硕华生命科学研究股份有限公司 — C26

Zhejiang SORFA Life Science Research Co., Ltd. ("SORFA Life", SORFA), founded in 2006, is a global high-tech supplier of life science lab consumables, with a core focus on biobanking consumables. Equipped with advanced smart manufacturing lines, we produce high-quality Cryovials with a daily output of up to 1,000,000 SBS standard units, alongside matching biobanking equipment including decappers and readers. Our products achieve full compatibility with mainstream automated biobanking systems such as Azenta, enabling seamless end-to-end automated sample traceability and batch processing. Certified by CE, ISO13485 and FDA, our reliable solutions are exported to key markets including Europe and the United States, serving global biobanks and research institutions worldwide.

ISBER
GLOBAL BIOBANKING CONGRESS
Shenzhen CHINA
APRIL 21-23, 2026

FACTS FOR SHENZHEN TRAVEL

GETTING FROM HONG KONG INTERNATIONAL AIRPORT TO SHENZHEN

OPTION 1: CROSS-BORDER BUS (EASIEST OPTION)

Travel time: 40 minutes (depending on border traffic)
Cost: HKD 150

1. Direct cross-border coaches depart from the airport.
2. Disembark at the border for immigration (exit Hong Kong, enter Mainland China).
3. Bus continues to Shenzhen after clearance.

Tip: Buses arrive via different border crossings. Liantang Port is closer to BGI, while Huanggang Port offers more frequent departures. Consider choosing the bus that departs the airport soonest.

OPTION 2: AIRPORT EXPRESS + HIGH-SPEED TRAIN

Travel time: ~1.5 hours total (plus transfer time)

1. Take the Airport Express from HK Airport to Kowloon or Hong Kong Station.
2. Transfer to West Kowloon Station.
3. Take a high-speed train to Shenzhen North Railway Station or Futian Station.

OPTION 3: MTR + BORDER CROSSING (BUDGET OPTION)

Travel time: ~2–3 hours

1. Take the Airport bus or Airport Express to the city.
2. Take the East Rail Line to Lo Wu or Lok Ma Chau.
3. Walk across the border.
4. Continue on Shenzhen Metro.

FROM SHENZHEN BAO'AN INTERNATIONAL AIRPORT TO YOUR HOTEL

Travel time: 60 minutes depending on hotel location.

OPTIONS:

1. **DiDi (recommended)** – English interface available
2. Taxi (use hotel name in Chinese)

CURRENCY TIPS

- Hong Kong uses **Hong Kong Dollars (HKD)**.
- Mainland China uses **Chinese Yuan (RMB / CNY)**.
- They are **not interchangeable**.
- Digital payments (Alipay & WeChat Pay) are widely used — cash is increasingly rare. Download both Alipay and WeChat and set up payment methods before travel.
- Exchange small amounts of cash before travel or at airport exchange counters.

ESSENTIAL APPS TO DOWNLOAD BEFORE ARRIVAL

- **DiDi** – Transportation (similar to Uber)
- **Alipay** – Payments
- **WeChat** – Payments & communication
- **Baidu Maps** – Navigation (Apple Maps is a good option, while Google Maps unreliable in China)
- **Baidu Translate/Youdao** - Translation (Chinanative support, Apple Translate works as well)
- **Trip.com** – Hotel & train bookings

TRAVEL & DOCUMENTATION

- Carry your **passport and visa** at all times.
- Required for:
  - » High-speed train travel
  - » Hotel check-in
  - » SIM card purchase
- Border crossing required when traveling from Hong Kong to Shenzhen
- Take a picture of your passport to have a digital copy on you at all times
- Carry your conference support letter and/or hotel booking.

OTHER ESSENTIALS

Electrical Plugs

- China uses **Type A, C, and I plugs**.
- Voltage: 220V.

Language Tips

- English is limited outside major hotels.
- Have key addresses saved in Chinese.

Emergency Numbers

- Police: 110
- Ambulance: 120

Cultural Tips

- Many services operate via QR codes.
- Some simple words to learn:
- Hello **(你好):** Nǐ hǎo => Pronounced: nee how
- Thank You **(谢谢):** Xièxie => Pronounced: shyeh-shyeh
- Please **(请):** Qǐng => Pronounced: ching (You'll often hear it used with gestures — for example when handing something over.)
- Yes **(是):** Shì => Pronounced: shr (like "sure" but shorter) OR more commonly in conversation: **(对)** Duì => Pronounced: dway (means "correct/right")
- No **(不是):** Bù shì => Pronounced: boo shr OR simple **(不)**Bù => Pronounced: boo
- Tipping is not required in mainland China.

INTERNET & CONNECTIVITY

- Download a **VPN before landing** (VPN downloads are restricted inside China).
- Purchase:
  - » An eSIM before travel, OR
  - » A SIM card at the airport
  - » A roaming plan with overseas connectivity
- Google products (Gmail, Google Maps, Drive, etc.) do **not** work without a VPN in Mainland China.

LEARN MORE AT WWW.ISBER.ORG/2026ISBERANNUAL

ISBER
GLOBAL BIOBANKING CONGRESS
Shenzhen CHINA
APRIL 21-23, 2026

Revolutionizing Next-Generation Automated Sample Storage Systems

Genepoint Technologies is committed to providing innovative, automated and comprehensive storage solutions for biological samples. Our independent R&D and in-house production ensure full process control, delivering the most stable products and reliable services.

Upholding the mission of "Inspire Life Exploration", Genepoint consistently pushes technological boundaries of automated sample storage and advances the practical applications of life sciences and biomedicine through ongoing innovation.

Genepoint is headquartered in Shanghai and has production, R&D, and product operation centers in both China and Singapore.

Genepoint Technologies
www.genepoint.com
info@genepoint.cn

QUALIFICATION in BIOREPOSITORY SCIENCE
a partnership between ISBER and ASCP

ISBER AND ASCP BOC ARE PLEASED TO OFFER THE QUALIFICATION IN REPOSITORY SCIENCE (QBRS) FOR BIOBANKERS.

Upon meeting specific educational and experience requirements for the qualification, candidates will be eligible to complete an online examination and, if successful, gain recognition for their skills and competencies as biobankers.

This qualification will further advance the field of biorepository science! Biobanks are vital to medical research and precision medicine and require qualified professionals to obtain high quality results that will be useful in advancing biomedicine.

Earn *your*
QUALIFICATION IN BIOREPOSITORY SCIENCE
For biobanking professionals

isber

ASCP BOC
ASCP BOARD OF CERTIFICATION®

NEW ROUTES AVAILABLE

Wondering if you can apply? Visit isber.org/qualification for details!

ONLINE COURSE:
ESSENTIALS OF BIOBANKING

- This online course provides learners with updated education on the key elements involved in planning, establishing, maintaining, and accessing a successful biobank
- Based on the 5th edition of ISBER Best Practices
- Recommended resource for QBRS exam (ASCP reading list)

Available in English and French

ISBER MEMBERS PRICE: $195USD
REDUCED PRICING FOR LMIC/UMIC COUNTRIES
Visit www.isber.org/EssentialsBiobanking

isber

CANADIAN TISSUE REPOSITORY NETWORK
RÉSEAU CANADIEN DE BANQUES DE TISSUS